Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: Possible therapeutic targets?
Nitric oxide (NO) is synthetized enzymatically from l-arginine (l-Arg) by three NO synthase isoforms, iNOS, eNOS and nNOS. The synthesis of NO is selectively inhibited by guanidino-substituted analogs of l-Arg or methylarginines such as asymmetric dimethylarginine (ADMA), which results from protein...
Saved in:
| Published in: | Pharmacology & therapeutics (Oxford) Vol. 140; no. 3; pp. 239 - 257 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Oxford
Elsevier
01.12.2013
|
| Subjects: | |
| ISSN: | 0163-7258, 1879-016X, 1879-016X, 0163-7258 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Nitric oxide (NO) is synthetized enzymatically from l-arginine (l-Arg) by three NO synthase isoforms, iNOS, eNOS and nNOS. The synthesis of NO is selectively inhibited by guanidino-substituted analogs of l-Arg or methylarginines such as asymmetric dimethylarginine (ADMA), which results from protein degradation in cells. Many disease states, including cardiovascular diseases and diabetes, are associated with increased plasma levels of ADMA. The N-terminal catalytic domain of these NOS isoforms binds the heme prosthetic group as well as the redox cofactor, tetrahydrobiopterin (BH(4)) associated with a regulatory protein, calmodulin (CaM). The enzymatic activity of NOS depends on substrate and cofactor availability. The importance of BH(4) as a critical regulator of eNOS function suggests that BH(4) may be a rational therapeutic target in vascular disease states. BH(4) oxidation appears to be a major contributor to vascular dysfunction associated with hypertension, ischemia/reperfusion injury, diabetes and other cardiovascular diseases as it leads to the increased formation of oxygen-derived radicals due to NOS uncoupling rather than NO. Accordingly, abnormalities in vascular NO production and transport result in endothelial dysfunction leading to various cardiovascular disorders. However, some disorders including a wide range of functions in the neuronal, immune and cardiovascular system were associated with the over-production of NO. Inhibition of the enzyme should be a useful approach to treat these pathologies. Therefore, it appears that both a lack and excess of NO production in diseases can have various important pathological implications. In this context, NOS modulators (exogenous and endogenous) and their therapeutic effects are discussed. |
|---|---|
| AbstractList | Nitric oxide (• NO) is synthetized enzymatically from L-arginine (L-Arg) by three NO synthase isoforms, iNOS, eNOS and nNOS. The synthesis of NO is selectively inhibited by guanidino-substituted analogs of L-Arg or methylarginines such as asymmetric dimethylarginine (ADMA), which results from protein degradation in cells. Many disease states, including cardiovascular diseases and diabetes, are associated with increased plasma levels of ADMA. The N-terminal catalytic domain of these NOS isoforms binds the heme prosthetic group as well as the redox cofactor, tetrahydrobiopterin (BH 4) associated with a regulatory protein, calmodulin (CaM). The enzymatic activity of NOS depends on substrate and cofactor availability. The importance of BH 4 as a critical regulator of eNOS function suggests that BH 4 may be a rational therapeutic target in vascular disease states. BH 4 oxidation appears to be a major contributor to vascular dysfunction associated with hypertension, ischemia/reperfusion injury, diabetes and other cardiovascular diseases as it leads to the increased formation of oxygen-derived radicals due to NOS uncoupling rather than NO. Accordingly, abnormalities in vascular NO production and transport result in endothelial dysfunction leading to various cardiovascular disorders. However, some disorders including a wide range of functions in the neuronal, immune and cardiovascular system were associated with the overproduction of NO. Inhibition of the enzyme should be a useful approach to treat these pathologies. Therefore, it appears that both a lack and excess of NO production in diseases can have various important pathological implications. In this context, NOS modulators (exogenous and endogenous) and their therapeutic effects are discussed. Nitric oxide (NO) is synthetized enzymatically from l-arginine (l-Arg) by three NO synthase isoforms, iNOS, eNOS and nNOS. The synthesis of NO is selectively inhibited by guanidino-substituted analogs of l-Arg or methylarginines such as asymmetric dimethylarginine (ADMA), which results from protein degradation in cells. Many disease states, including cardiovascular diseases and diabetes, are associated with increased plasma levels of ADMA. The N-terminal catalytic domain of these NOS isoforms binds the heme prosthetic group as well as the redox cofactor, tetrahydrobiopterin (BH(4)) associated with a regulatory protein, calmodulin (CaM). The enzymatic activity of NOS depends on substrate and cofactor availability. The importance of BH(4) as a critical regulator of eNOS function suggests that BH(4) may be a rational therapeutic target in vascular disease states. BH(4) oxidation appears to be a major contributor to vascular dysfunction associated with hypertension, ischemia/reperfusion injury, diabetes and other cardiovascular diseases as it leads to the increased formation of oxygen-derived radicals due to NOS uncoupling rather than NO. Accordingly, abnormalities in vascular NO production and transport result in endothelial dysfunction leading to various cardiovascular disorders. However, some disorders including a wide range of functions in the neuronal, immune and cardiovascular system were associated with the over-production of NO. Inhibition of the enzyme should be a useful approach to treat these pathologies. Therefore, it appears that both a lack and excess of NO production in diseases can have various important pathological implications. In this context, NOS modulators (exogenous and endogenous) and their therapeutic effects are discussed. Nitric oxide (NO) is synthetized enzymatically from l-arginine (l-Arg) by three NO synthase isoforms, iNOS, eNOS and nNOS. The synthesis of NO is selectively inhibited by guanidino-substituted analogs of l-Arg or methylarginines such as asymmetric dimethylarginine (ADMA), which results from protein degradation in cells. Many disease states, including cardiovascular diseases and diabetes, are associated with increased plasma levels of ADMA. The N-terminal catalytic domain of these NOS isoforms binds the heme prosthetic group as well as the redox cofactor, tetrahydrobiopterin (BH(4)) associated with a regulatory protein, calmodulin (CaM). The enzymatic activity of NOS depends on substrate and cofactor availability. The importance of BH(4) as a critical regulator of eNOS function suggests that BH(4) may be a rational therapeutic target in vascular disease states. BH(4) oxidation appears to be a major contributor to vascular dysfunction associated with hypertension, ischemia/reperfusion injury, diabetes and other cardiovascular diseases as it leads to the increased formation of oxygen-derived radicals due to NOS uncoupling rather than NO. Accordingly, abnormalities in vascular NO production and transport result in endothelial dysfunction leading to various cardiovascular disorders. However, some disorders including a wide range of functions in the neuronal, immune and cardiovascular system were associated with the over-production of NO. Inhibition of the enzyme should be a useful approach to treat these pathologies. Therefore, it appears that both a lack and excess of NO production in diseases can have various important pathological implications. In this context, NOS modulators (exogenous and endogenous) and their therapeutic effects are discussed.Nitric oxide (NO) is synthetized enzymatically from l-arginine (l-Arg) by three NO synthase isoforms, iNOS, eNOS and nNOS. The synthesis of NO is selectively inhibited by guanidino-substituted analogs of l-Arg or methylarginines such as asymmetric dimethylarginine (ADMA), which results from protein degradation in cells. Many disease states, including cardiovascular diseases and diabetes, are associated with increased plasma levels of ADMA. The N-terminal catalytic domain of these NOS isoforms binds the heme prosthetic group as well as the redox cofactor, tetrahydrobiopterin (BH(4)) associated with a regulatory protein, calmodulin (CaM). The enzymatic activity of NOS depends on substrate and cofactor availability. The importance of BH(4) as a critical regulator of eNOS function suggests that BH(4) may be a rational therapeutic target in vascular disease states. BH(4) oxidation appears to be a major contributor to vascular dysfunction associated with hypertension, ischemia/reperfusion injury, diabetes and other cardiovascular diseases as it leads to the increased formation of oxygen-derived radicals due to NOS uncoupling rather than NO. Accordingly, abnormalities in vascular NO production and transport result in endothelial dysfunction leading to various cardiovascular disorders. However, some disorders including a wide range of functions in the neuronal, immune and cardiovascular system were associated with the over-production of NO. Inhibition of the enzyme should be a useful approach to treat these pathologies. Therefore, it appears that both a lack and excess of NO production in diseases can have various important pathological implications. In this context, NOS modulators (exogenous and endogenous) and their therapeutic effects are discussed. Nitric oxide (NO) is synthetized enzymatically from l-arginine (l-Arg) by three NO synthase isoforms, iNOS, eNOS and nNOS. The synthesis of NO is selectively inhibited by guanidino-substituted analogs of l-Arg or methylarginines such as asymmetric dimethylarginine (ADMA), which results from protein degradation in cells. Many disease states, including cardiovascular diseases and diabetes, are associated with increased plasma levels of ADMA. The N-terminal catalytic domain of these NOS isoforms binds the heme prosthetic group as well as the redox cofactor, tetrahydrobiopterin (BH₄) associated with a regulatory protein, calmodulin (CaM). The enzymatic activity of NOS depends on substrate and cofactor availability. The importance of BH₄ as a critical regulator of eNOS function suggests that BH₄ may be a rational therapeutic target in vascular disease states. BH₄ oxidation appears to be a major contributor to vascular dysfunction associated with hypertension, ischemia/reperfusion injury, diabetes and other cardiovascular diseases as it leads to the increased formation of oxygen-derived radicals due to NOS uncoupling rather than NO. Accordingly, abnormalities in vascular NO production and transport result in endothelial dysfunction leading to various cardiovascular disorders. However, some disorders including a wide range of functions in the neuronal, immune and cardiovascular system were associated with the over-production of NO. Inhibition of the enzyme should be a useful approach to treat these pathologies. Therefore, it appears that both a lack and excess of NO production in diseases can have various important pathological implications. In this context, NOS modulators (exogenous and endogenous) and their therapeutic effects are discussed. |
| Author | Lorin, Julie Rochette, Luc Lorgis, Luc Guilland, Jean-Claude Vergely, Catherine Zeller, Marianne Cottin, Yves |
| Author_xml | – sequence: 1 givenname: Luc surname: Rochette fullname: Rochette, Luc – sequence: 2 givenname: Julie surname: Lorin fullname: Lorin, Julie – sequence: 3 givenname: Marianne surname: Zeller fullname: Zeller, Marianne – sequence: 4 givenname: Jean-Claude surname: Guilland fullname: Guilland, Jean-Claude – sequence: 5 givenname: Luc surname: Lorgis fullname: Lorgis, Luc – sequence: 6 givenname: Yves surname: Cottin fullname: Cottin, Yves – sequence: 7 givenname: Catherine surname: Vergely fullname: Vergely, Catherine |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27863985$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23859953$$D View this record in MEDLINE/PubMed https://ube.hal.science/hal-03434261$$DView record in HAL |
| BookMark | eNqF0ktv1DAQAGALFdFt4S-gXJDgkOBXYocDVVXRFmkFHEDiZk38IF5lk8V2VvTf43SXVuLS00j2N6PRzJyhk3EaLUIFwRXBpHm_qXY9hG3qbYCKYsIqLCqM-TO0IlK0ZTY_T9AqB1YKWstTdBbjBmfBMX2BTimTddvWbIWmLz4Fr4vpjze2iHdj6iHawo-973zy01jAaO5_Ifl9FinYGPN_oSEYP-0h6nmAUBgfbc6MH4pvU4y-G2xx397OzinXTxB-2RQvXqLnDoZoXx3jOfpx_en71W25_nrz-epyXeqaylSSFrfE0E5wKTnBQMEBN52TjewYOAeSY0O1NsJ1TjhdWwqE6lZwIjtsGDtH7w51exjULvgthDs1gVe3l2u1vGHGGacN2ZNs3x7sLky_ZxuT2vqo7TDAaKc5KiIYq6loJH-a8lyVEEYX-vpI525rzUMT_2afwZsjyDOEwQUYtY-PTsiGtbLOTh6cDnmywboHQrBazkFt1OM5qOUcFBYqLzunfvwvVfsEy1pTAD88XeAvc7nCMQ |
| CODEN | PHTHDT |
| CitedBy_id | crossref_primary_10_3389_fendo_2023_1226687 crossref_primary_10_1016_j_ihj_2016_01_011 crossref_primary_10_1016_j_ecoenv_2018_08_029 crossref_primary_10_7717_peerj_18503 crossref_primary_10_3390_chemistry4040076 crossref_primary_10_1177_1559325819853651 crossref_primary_10_3390_app122211343 crossref_primary_10_1016_j_jtice_2016_11_003 crossref_primary_10_1111_bph_14457 crossref_primary_10_3390_biomedicines11051452 crossref_primary_10_3389_fphar_2022_898797 crossref_primary_10_1155_2016_3690628 crossref_primary_10_1515_biol_2022_0026 crossref_primary_10_1007_s13204_021_02096_9 crossref_primary_10_1186_s12933_023_02058_1 crossref_primary_10_1371_journal_pone_0156793 crossref_primary_10_1530_JOE_14_0662 crossref_primary_10_1016_j_ejps_2016_09_004 crossref_primary_10_1111_1755_5922_12134 crossref_primary_10_1007_s10565_014_9291_4 crossref_primary_10_1016_j_bbadis_2025_167968 crossref_primary_10_1186_1475_2840_13_88 crossref_primary_10_3390_ijms252212364 crossref_primary_10_1016_j_micpath_2020_104303 crossref_primary_10_1155_2023_1164147 crossref_primary_10_1155_2018_8194721 crossref_primary_10_1016_j_clinbiochem_2023_110703 crossref_primary_10_3389_fendo_2021_752410 crossref_primary_10_3390_ijms251910296 crossref_primary_10_1016_j_iccn_2022_103336 crossref_primary_10_1016_j_pharmthera_2017_08_015 crossref_primary_10_3390_ijms18071426 crossref_primary_10_3389_frai_2024_1446640 crossref_primary_10_1080_00365513_2017_1286518 crossref_primary_10_3390_antiox7080107 crossref_primary_10_3389_fphys_2016_00555 crossref_primary_10_1097_MPA_0000000000002139 crossref_primary_10_1007_s43450_023_00442_2 crossref_primary_10_3389_fcimb_2023_1220877 crossref_primary_10_1002_dmrr_2836 crossref_primary_10_1002_hsr2_70544 crossref_primary_10_1002_jnr_24030 crossref_primary_10_3390_ijerph192013521 crossref_primary_10_3389_fphar_2020_569914 crossref_primary_10_1097_FM9_0000000000000276 crossref_primary_10_1002_jbt_23393 crossref_primary_10_1038_s41420_023_01399_w crossref_primary_10_1038_s41374_018_0161_1 crossref_primary_10_1007_s00380_017_1055_7 crossref_primary_10_1016_j_brainres_2024_149340 crossref_primary_10_1016_j_nut_2017_07_005 crossref_primary_10_1016_j_biopha_2020_110043 crossref_primary_10_3390_ijms25137284 crossref_primary_10_1002_eji_202250071 crossref_primary_10_2174_1381612826666200318152049 crossref_primary_10_1016_j_jinorgbio_2018_01_009 crossref_primary_10_1016_j_jphotobiol_2015_05_019 crossref_primary_10_1080_10715762_2017_1322205 crossref_primary_10_1155_2016_5057405 crossref_primary_10_4239_wjd_v16_i2_100395 crossref_primary_10_1016_j_phrs_2019_104601 crossref_primary_10_1155_2015_416235 crossref_primary_10_3389_fchem_2022_836478 crossref_primary_10_1016_j_urology_2016_02_004 crossref_primary_10_1016_j_cryobiol_2024_104849 crossref_primary_10_1080_17435390_2019_1663288 crossref_primary_10_1016_S1875_5364_25_60823_5 crossref_primary_10_1016_j_molliq_2019_112352 crossref_primary_10_1186_s11658_021_00283_8 crossref_primary_10_1080_10498850_2015_1082525 crossref_primary_10_1161_ATVBAHA_114_304674 crossref_primary_10_3390_cells11071226 crossref_primary_10_1016_j_mvr_2022_104468 crossref_primary_10_3390_ijms22157979 crossref_primary_10_1111_and_14138 crossref_primary_10_1111_1440_1681_12796 crossref_primary_10_1016_j_jep_2025_120285 crossref_primary_10_1002_slct_202500890 crossref_primary_10_1016_j_ancard_2017_04_017 crossref_primary_10_1097_CRD_0000000000000581 crossref_primary_10_1007_s00223_019_00573_6 crossref_primary_10_1016_j_bcp_2021_114673 crossref_primary_10_1016_j_tiv_2019_104661 crossref_primary_10_3390_molecules25102417 crossref_primary_10_1007_s40272_022_00508_z crossref_primary_10_1007_s12011_016_0793_1 crossref_primary_10_1111_1440_1681_12550 crossref_primary_10_1080_01913123_2016_1278065 crossref_primary_10_1016_j_jff_2016_07_002 crossref_primary_10_3390_ijms22168889 crossref_primary_10_1016_j_heliyon_2023_e16097 crossref_primary_10_1016_j_sciaf_2025_e02861 crossref_primary_10_1007_s11596_023_2818_2 crossref_primary_10_1371_journal_pone_0250126 crossref_primary_10_3892_mmr_2017_7181 crossref_primary_10_52586_4926 crossref_primary_10_1016_j_acvd_2021_10_013 crossref_primary_10_3109_00207454_2014_930740 crossref_primary_10_1590_s0102_865020190110000002 crossref_primary_10_1371_journal_pone_0206814 crossref_primary_10_1016_j_pharmthera_2019_05_015 crossref_primary_10_1016_j_phrs_2021_105943 crossref_primary_10_1038_s41440_018_0181_7 crossref_primary_10_1371_journal_pone_0131439 crossref_primary_10_1080_00207454_2018_1486828 crossref_primary_10_2478_fzm_2022_0002 crossref_primary_10_3389_fimmu_2022_1039241 crossref_primary_10_1007_s10534_014_9807_7 crossref_primary_10_1016_j_ahj_2022_08_003 crossref_primary_10_1039_D1RA05819C crossref_primary_10_1080_87559129_2017_1410172 crossref_primary_10_1155_2019_2340392 crossref_primary_10_3390_cancers13040893 crossref_primary_10_3389_fphar_2024_1443560 crossref_primary_10_1097_HJH_0000000000001898 crossref_primary_10_1177_2040622319891539 crossref_primary_10_1086_689289 crossref_primary_10_1002_jcb_29122 crossref_primary_10_1016_j_advms_2015_10_006 crossref_primary_10_1016_j_carpath_2014_09_002 crossref_primary_10_3390_jcm10132832 crossref_primary_10_1016_j_tips_2015_03_005 crossref_primary_10_1111_bph_15694 crossref_primary_10_1016_j_fsi_2023_109027 crossref_primary_10_1155_2014_102158 crossref_primary_10_3389_fcvm_2022_984472 crossref_primary_10_3389_fphar_2022_1025104 crossref_primary_10_1016_j_biopha_2018_01_038 crossref_primary_10_1016_j_taap_2015_10_014 crossref_primary_10_1016_j_jep_2024_118322 crossref_primary_10_1039_c8pp00481a crossref_primary_10_1152_japplphysiol_01149_2014 crossref_primary_10_3390_ijms19123998 crossref_primary_10_1159_000533592 crossref_primary_10_1016_j_bbagen_2019_04_004 crossref_primary_10_3390_cells10061494 crossref_primary_10_3109_14767058_2014_964676 crossref_primary_10_52645_MJHS_2024_2_05 crossref_primary_10_1038_s41371_021_00602_8 crossref_primary_10_1093_ajh_hpt292 crossref_primary_10_1016_j_cbi_2023_110683 crossref_primary_10_3892_etm_2019_7772 crossref_primary_10_3389_fphys_2021_687381 crossref_primary_10_1111_jnc_15807 crossref_primary_10_1186_s13098_025_01718_4 crossref_primary_10_1152_ajprenal_00624_2017 crossref_primary_10_1155_2022_9154295 crossref_primary_10_1016_j_acvd_2017_06_001 crossref_primary_10_1016_j_biopha_2015_11_001 crossref_primary_10_1016_j_acvd_2023_07_007 crossref_primary_10_1089_ars_2024_0774 crossref_primary_10_3390_ijms24010489 crossref_primary_10_1016_j_ejmech_2019_04_030 crossref_primary_10_1210_clinem_dgaa954 crossref_primary_10_1097_PCC_0000000000002049 crossref_primary_10_1111_and_13487 crossref_primary_10_1016_j_jash_2016_06_036 crossref_primary_10_1007_s00210_024_03154_z crossref_primary_10_1080_10408398_2018_1491022 crossref_primary_10_1016_j_cbi_2023_110793 crossref_primary_10_1016_j_inoche_2025_114006 crossref_primary_10_1080_10408444_2019_1583167 crossref_primary_10_3390_agriculture12050588 crossref_primary_10_1007_s00702_021_02448_3 crossref_primary_10_1038_nrcardio_2016_20 crossref_primary_10_1007_s11883_024_01223_5 crossref_primary_10_1016_j_cej_2025_160295 crossref_primary_10_3389_fcvm_2021_649813 crossref_primary_10_3923_ijp_2019_642_650 crossref_primary_10_3389_fcvm_2017_00079 crossref_primary_10_1016_j_mvr_2018_03_012 crossref_primary_10_1016_j_ejphar_2025_177863 crossref_primary_10_1093_burnst_tkaf007 crossref_primary_10_1177_2045894019875417 crossref_primary_10_3390_antiox12030574 crossref_primary_10_1016_j_chemosphere_2018_05_049 crossref_primary_10_1016_j_ijcard_2014_03_085 crossref_primary_10_1016_j_niox_2018_01_002 crossref_primary_10_1111_cbdd_14248 crossref_primary_10_4239_wjd_v16_i5_104409 crossref_primary_10_31083_j_jin2204103 crossref_primary_10_3390_ijms25116047 crossref_primary_10_3390_antiox6030051 crossref_primary_10_1016_j_niox_2017_11_005 crossref_primary_10_3390_nu13020534 crossref_primary_10_1038_s41371_020_0344_2 crossref_primary_10_1016_j_acvd_2020_03_020 crossref_primary_10_1016_j_jep_2015_11_019 crossref_primary_10_1016_j_sajb_2023_12_013 crossref_primary_10_2217_fca_2016_0008 crossref_primary_10_1016_j_phrs_2023_106953 crossref_primary_10_1016_j_saa_2021_120728 crossref_primary_10_1111_odi_12327 crossref_primary_10_1016_j_tem_2017_11_005 crossref_primary_10_3390_antiox9060525 crossref_primary_10_1111_cpr_12400 crossref_primary_10_3389_fvets_2022_848912 crossref_primary_10_1016_j_ccm_2025_04_010 crossref_primary_10_1093_humrep_deab225 crossref_primary_10_1111_jfbc_13463 crossref_primary_10_3390_ijms20030705 crossref_primary_10_1016_j_addr_2021_113869 crossref_primary_10_1371_journal_pone_0084576 crossref_primary_10_3390_molecules27123724 crossref_primary_10_1002_jcb_26575 crossref_primary_10_1080_13543776_2019_1567711 crossref_primary_10_1161_HYPERTENSIONAHA_114_03777 crossref_primary_10_1016_j_cbi_2025_111387 crossref_primary_10_1016_j_bcp_2016_07_010 crossref_primary_10_1016_j_tem_2021_08_011 crossref_primary_10_1002_j_2040_4603_2015_tb00663_x crossref_primary_10_1002_mgg3_1011 crossref_primary_10_1186_s40348_015_0017_3 crossref_primary_10_1186_s13071_015_1149_y crossref_primary_10_1371_journal_pone_0188439 crossref_primary_10_1016_j_lfs_2019_01_026 crossref_primary_10_3390_ijms15033989 crossref_primary_10_1186_s12872_020_01819_0 crossref_primary_10_3390_ijms21249427 crossref_primary_10_1038_s41392_024_01916_y crossref_primary_10_1016_j_isci_2025_112052 crossref_primary_10_1177_2045893216677519 crossref_primary_10_1016_j_lfs_2020_117821 crossref_primary_10_1152_japplphysiol_00055_2018 crossref_primary_10_1515_oncologie_2023_0280 crossref_primary_10_3389_fcvm_2022_895797 crossref_primary_10_1039_C8RA08867E crossref_primary_10_3389_fnins_2018_00196 crossref_primary_10_1016_j_pharmthera_2016_07_008 crossref_primary_10_1007_s12272_015_0671_y crossref_primary_10_3390_metabo11120805 crossref_primary_10_1016_j_intimp_2021_108250 crossref_primary_10_1177_0300060517731684 crossref_primary_10_3390_cells12182278 crossref_primary_10_1016_j_acvd_2014_02_001 crossref_primary_10_1155_2015_826805 crossref_primary_10_1152_japplphysiol_00445_2022 crossref_primary_10_1002_jat_4254 crossref_primary_10_3390_ijms24010449 crossref_primary_10_1016_j_lfs_2019_01_030 crossref_primary_10_3389_fonc_2023_1165326 crossref_primary_10_1007_s10654_025_01295_w crossref_primary_10_1007_s11906_015_0596_3 crossref_primary_10_1016_j_lfs_2019_117239 crossref_primary_10_1016_j_niox_2018_10_007 crossref_primary_10_1016_j_abb_2015_11_030 crossref_primary_10_1016_j_ijpharm_2025_125885 crossref_primary_10_31083_j_fbl2905190 crossref_primary_10_1007_s00210_025_04238_0 crossref_primary_10_1007_s00395_024_01038_0 crossref_primary_10_1111_jocd_15975 crossref_primary_10_3390_antiox11061188 crossref_primary_10_1016_j_dnarep_2024_103730 crossref_primary_10_1186_s12953_016_0100_2 crossref_primary_10_3389_fvets_2020_00225 crossref_primary_10_3390_genes13111998 crossref_primary_10_3390_molecules24234259 crossref_primary_10_1016_j_heliyon_2024_e29160 crossref_primary_10_1007_s11010_023_04835_8 crossref_primary_10_1186_s40001_023_01161_z crossref_primary_10_22376_ijpbs_2018_9_3_p38_46 crossref_primary_10_1016_j_colsurfb_2017_07_031 crossref_primary_10_1016_j_jff_2016_12_029 crossref_primary_10_3389_fimmu_2022_1098725 crossref_primary_10_1016_j_numecd_2023_07_024 crossref_primary_10_1139_cjpp_2014_0353 crossref_primary_10_3390_antiox11081587 crossref_primary_10_1007_s11011_025_01620_y crossref_primary_10_1016_j_bjp_2015_05_002 crossref_primary_10_3390_ijms22094540 crossref_primary_10_1371_journal_pone_0174435 crossref_primary_10_3390_antiox11040751 crossref_primary_10_3390_ijms241511986 crossref_primary_10_1161_ATVBAHA_119_313138 crossref_primary_10_52586_S556 crossref_primary_10_1155_2018_3402809 crossref_primary_10_1016_j_biopha_2018_04_144 crossref_primary_10_1007_s10495_024_02057_x crossref_primary_10_3892_mmr_2017_8314 crossref_primary_10_1183_16000617_0114_2018 crossref_primary_10_1021_acsinfecdis_5c00378 crossref_primary_10_1016_j_bas_2023_101745 crossref_primary_10_3390_ijms25063360 crossref_primary_10_1155_2021_2895893 crossref_primary_10_3390_molecules25153322 crossref_primary_10_1007_s13580_015_0091_4 crossref_primary_10_7554_eLife_62589 crossref_primary_10_1016_j_lfs_2022_120605 crossref_primary_10_1038_s41392_023_01430_7 crossref_primary_10_3390_ijms21239262 crossref_primary_10_1007_s00484_017_1484_0 crossref_primary_10_3389_fmars_2022_905147 crossref_primary_10_1007_s43440_025_00781_y crossref_primary_10_2174_0118743641391527250714045351 crossref_primary_10_1016_j_biopha_2021_111370 crossref_primary_10_3390_jcm9030879 crossref_primary_10_1016_j_etap_2014_09_009 crossref_primary_10_3390_cells8050388 crossref_primary_10_3390_antiox14040377 crossref_primary_10_3390_toxics6030044 crossref_primary_10_1002_admi_202002241 crossref_primary_10_3390_brainsci13020310 crossref_primary_10_1016_j_drudis_2013_11_010 crossref_primary_10_3390_biom10071065 crossref_primary_10_3390_ijms18040841 crossref_primary_10_1515_hsz_2013_0241 crossref_primary_10_1039_C8RA09763A crossref_primary_10_1111_jcmm_13122 crossref_primary_10_4236_mri_2014_32006 crossref_primary_10_1093_infdis_jiaa643 crossref_primary_10_1155_2019_8954201 crossref_primary_10_1007_s13346_024_01517_w crossref_primary_10_3390_ijms21186803 crossref_primary_10_1016_j_hlc_2016_08_002 crossref_primary_10_3390_ijms24087569 crossref_primary_10_1155_2022_3261213 crossref_primary_10_1016_j_ghir_2014_08_001 crossref_primary_10_3390_nu14163265 crossref_primary_10_1016_j_pharmthera_2015_10_006 crossref_primary_10_1016_j_heliyon_2024_e24040 crossref_primary_10_1111_jcmm_16073 crossref_primary_10_3390_ijms23063274 crossref_primary_10_1002_jcp_26466 crossref_primary_10_3390_ijms18112258 crossref_primary_10_3390_nu15040972 crossref_primary_10_1089_neu_2015_4340 crossref_primary_10_1016_j_bbrc_2017_11_009 crossref_primary_10_1097_MNH_0000000000000535 |
| Cites_doi | 10.1124/mol.112.079855 10.1177/1358836X0501000111 10.1111/j.1742-7843.2011.00785.x 10.1097/01.CCM.0000105581.01815.C6 10.2741/3174 10.1093/eurheartj/ehp061 10.1016/j.phrs.2009.08.002 10.1161/CIRCULATIONAHA.106.684795 10.1007/s00018-012-1010-9 10.1016/j.niox.2011.03.002 10.1021/jm101071n 10.1016/j.pharmthera.2010.02.005 10.1016/0891-5849(95)91457-3 10.1016/j.freeradbiomed.2012.02.046 10.1124/jpet.110.168724 10.1517/14728222.2012.688030 10.1016/S0891-5849(97)00282-7 10.3109/14756366.2011.573480 10.1139/Y09-136 10.1016/j.ijcard.2007.08.066 10.1016/j.freeradbiomed.2008.03.020 10.1016/j.ijcard.2010.10.029 10.1161/01.ATV.0000110785.96039.f6 10.1016/j.atherosclerosis.2010.09.018 10.1093/eurheartj/ehr304 10.1097/00005344-199901000-00012 10.1016/j.tips.2011.07.006 10.1097/00004872-199917110-00003 10.1093/oxfordjournals.aje.a112813 10.1111/j.1476-5381.1990.tb14151.x 10.1016/j.abb.2009.03.015 10.1089/ars.2006.8.1865 10.1074/jbc.M603606200 10.1016/j.vph.2010.03.002 10.1007/s10522-012-9379-2 10.1161/01.CIR.0000027109.14149.67 10.1093/ajcn/79.4.537 10.1074/jbc.M603671200 10.1006/abio.2001.5575 10.1016/j.ijcard.2010.09.004 10.1038/sj.bjp.0702298 10.1161/HYPERTENSIONAHA.107.093450 10.1016/j.atherosclerosis.2010.11.014 10.1097/00041433-199702000-00007 10.1124/jpet.107.128009 10.1053/meta.2002.33349 10.1210/en.2007-1558 10.1007/s00395-009-0041-3 10.1016/j.drudis.2006.04.003 10.1042/CS20080079 10.1002/iub.61 10.1089/ars.2009.2585 10.1034/j.1600-0773.2000.d01-36.x 10.1016/j.cccn.2003.10.006 10.1016/j.mam.2004.09.003 10.1007/978-1-61779-382-0_17 10.1111/j.1476-5381.2011.01308.x 10.1074/jbc.M401853200 10.1021/jm990111c 10.1152/ajpregu.90506.2008 10.1074/jbc.M302227200 10.1007/s00424-009-0765-9 10.1042/bj3360001 10.1038/ajh.2008.218 10.1074/jbc.271.38.23317 10.1089/ars.2007.1989 10.1016/S0895-7061(02)02278-1 10.59566/IJBS.2008.4255 10.1016/j.vph.2012.02.004 10.1002/cmdc.200800301 10.1016/j.bbrc.2008.10.080 10.1001/jama.295.1.58 10.1021/jm100416n 10.1016/j.yjmcc.2008.02.275 10.1161/ATVBAHA.107.156786 10.1155/2012/318087 10.1161/01.CIR.0000091083.61609.DF 10.5483/BMBRep.2010.43.9.584 10.1038/ajh.2008.260 10.1016/j.abb.2003.07.007 10.1097/FJC.0b013e3181865f28 10.1161/HYPERTENSIONAHA.108.111120 10.1161/CIRCULATIONAHA.107.737031 10.33549/physiolres.931982 10.1021/jm050187a 10.1161/hc4601.098514 10.2337/db06-0699 10.1124/jpet.102.036871 10.2119/molmed.2011.00103 10.1016/j.yjmcc.2011.05.017 10.1161/CIRCULATIONAHA.107.717702 10.1056/NEJMoa060900 10.1016/j.pharmthera.2006.06.007 10.1093/cvr/cvq366 10.1016/S0040-8166(96)80067-X 10.1002/med.20005 10.1016/j.hrthm.2009.12.009 10.2337/dc12-1084 10.1093/cvr/cvq412 10.1161/01.CIR.99.9.1141 10.2174/1875397301005010072 10.1161/01.CIR.0000060496.23144.A7 10.1152/ajpheart.00998.2007 10.1016/j.tips.2008.10.003 10.1038/aps.2009.58 10.1016/j.ccr.2010.12.020 10.1007/s10863-012-9429-0 10.1161/CIRCULATIONAHA.110.985150 10.1517/13543776.2011.584870 10.1016/0891-5849(94)90147-3 10.1111/j.1463-1326.2010.01266.x 10.1038/nrd3358 10.1053/meta.2003.50048 10.1515/CCLM.2003.225 10.1016/j.mam.2005.07.001 10.1517/17425250902785172 10.1161/ATVBAHA.108.162768 10.1210/jc.2003-030087 10.1111/j.1474-9726.2007.00271.x 10.1136/heartjnl-2011-301372 10.1161/HYPERTENSIONAHA.111.187310 10.1016/j.niox.2011.04.004 10.1161/01.RES.0000181286.44222.61 10.1016/j.pharmthera.2012.09.007 10.1093/cvr/cvr233 10.1074/jbc.M011469200 10.1016/j.molcel.2008.12.013 10.1001/archinte.163.16.1933 10.1152/ajpheart.01103.2007 10.1016/j.chemphyslip.2010.07.004 10.1016/j.it.2010.01.006 10.1016/S0140-6736(01)07184-7 10.1021/jm300521m 10.1016/j.freeradbiomed.2006.02.020 10.1016/j.yjmcc.2011.09.006 10.1007/s001250051551 10.1016/j.pharmthera.2008.08.005 10.1080/10715760701885380 10.1074/jbc.M410241200 10.1038/sj.emboj.7601794 10.1016/j.atherosclerosis.2011.09.011 10.1016/j.phrs.2009.07.001 10.1172/JCI31093 10.1111/j.1472-8206.1998.tb00947.x 10.1152/ajpheart.01205.2011 10.1152/ajpheart.00823.2007 10.1161/01.RES.0000052990.68216.EF 10.1161/CIRCULATIONAHA.108.838268 10.1042/BJ20110293 10.3109/08830185.2012.665108 10.1016/j.vph.2012.02.012 10.1371/journal.pone.0009462 10.1016/j.niox.2010.03.001 10.1080/10715760100301491 10.1016/S0008-6363(98)00146-1 10.1161/01.HYP.0000034738.79310.06 10.1021/jm4000984 10.1016/S0008-6363(00)00048-1 10.1016/S0002-9149(01)02063-X 10.1161/01.ATV.16.1.44 10.1136/heart.87.3.264 10.1161/01.CIR.100.14.1515 10.1046/j.1472-8206.2003.00199.x 10.1155/2012/656247 10.1016/j.freeradbiomed.2010.12.018 10.1146/annurev.nutr.26.061505.111320 10.1161/01.ATV.21.5.804 10.1038/sj.bjp.0707143 10.1002/ijc.25366 10.1021/ja908544f 10.1159/000329951 10.2174/157016108784911984 10.1042/0264-6021:3570593 10.1111/j.1476-5381.2011.01500.x 10.1038/sj.bjp.0702430 10.1161/01.ATV.0000128897.54893.26 10.1371/journal.pone.0036224 10.1016/j.bmc.2012.12.019 10.1161/HYPERTENSIONAHA.110.152959 10.1016/j.mam.2005.07.015 10.1038/nchembio.115 10.1016/j.clinbiochem.2006.08.004 10.1189/jlb.0610322 10.1093/cvr/cvs182 10.1016/j.phrs.2009.07.016 10.1161/CIRCULATIONAHA.106.612325 10.1111/j.1365-2796.2008.01965.x 10.1016/0140-6736(92)90865-Z 10.1093/ndt/gfn357 10.2337/db06-1772 10.1097/00004872-199715080-00015 10.1016/j.jvs.2010.04.085 10.1016/j.atherosclerosis.2012.09.029 10.1016/j.biocel.2007.10.011 10.1152/ajprenal.00221.2004 10.1016/j.pharmthera.2007.08.001 |
| ContentType | Journal Article |
| Copyright | 2014 INIST-CNRS 2013. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: 2014 INIST-CNRS – notice: 2013. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 1XC VOOES |
| DOI | 10.1016/j.pharmthera.2013.07.004 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic AGRICOLA |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1879-016X 0163-7258 |
| EndPage | 257 |
| ExternalDocumentID | oai:HAL:hal-03434261v1 23859953 27863985 10_1016_j_pharmthera_2013_07_004 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- --K --M .GJ .~1 0R~ 123 1B1 1RT 1~. 1~5 29O 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9DU 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO AAYXX ABFNM ABMAC ABWVN ABXDB ABZDS ACDAQ ACGFO ACIUM ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AFFNX AFJKZ AFPUW AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC C45 CITATION CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMT HVGLF HZ~ IHE J1W K-O KOM L7B M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SCC SDF SDG SDP SES SEW SPCBC SPT SSP SSZ T5K TEORI WUQ Y6R ZGI ZXP ~G- ~HD AACTN BNPGV IQODW RIG SSH AFKWA AJOXV AMFUW CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 1XC VOOES |
| ID | FETCH-LOGICAL-c528t-19091d2b7488410a2afa4dbf868b3affa840d2ccd7fbf7fc5e2a12c97418b0d33 |
| ISICitedReferencesCount | 384 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000326422200003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0163-7258 1879-016X |
| IngestDate | Tue Oct 14 20:32:50 EDT 2025 Sun Sep 28 08:31:07 EDT 2025 Wed Oct 01 14:41:19 EDT 2025 Wed Feb 19 01:52:23 EST 2025 Wed Apr 02 07:25:19 EDT 2025 Tue Nov 18 21:44:05 EST 2025 Sat Nov 29 04:49:51 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Drug Oxidative stress Free radicals Targeting Enzyme BH Enzyme inhibitor Cardiovascular disease ADMA NO synthases Nitric-oxide synthase Free radical Research and development Treatment NO inhibitors Asymmetric dimethylarginine Oxidoreductases Mechanism of action GTP TocH alanine-glyoxylate aminotransferase 2 PRMT calmodulin AP-1 protein arginine methyl transferase glutathioneperoxidase NADPH oxidase DMGV NTPH 7,8-dihydroneopterin 30 triphosphate uric acid cationic amino acids monoamine oxidase total plasma homocysteine redox factor-1 PTPS nitric oxide AF symmetric dimethylarginine CAAs tyrosine hydroxylase cationic amino acid transporters AT ARE superoxide dismutase MAO dimethylamines ApoE-KO peroxyredoxin nuclear factor erythroid 2-related factor 2 ERK AscH(−) heat shock protein metallothionein α-keto-δ-(N(G),N(G)-dimethylguanidino)valeric acid GTP cyclohydrolase 1 mitogen-activated protein kinase S-adenosyl-l-homocysteine l-Arg Nrf2 N-nitro-l-arginine NOHA SR CATs HIF AGXT2 FMN dimethylarginine dimethylaminohydrolases SOD hypoxia-inducible factor cardiovascular CR DHFR y+LAT transporters DDAHs CV flavin mononucleotide TH PAH N(G)-monomethyl-l-arginine leukocyte telomere length forkhead protein oxidative stress extracellular signal-regulated kinase GTP-CH SDMA nuclear factor κB JNK OGG1 N-omega-hydroxy-l-arginine DM sepiapterin reductase MDA UA CaM dihydrofolate reductase NF-κB atrial fibrillation glutathione peroxidases nicotinamide dinucleotide phosphate activator protein 1 RNS Prx pterin-4a-carbinolamine dehydratase Trx malondialdehyde carbonyl reductase apolipoprotein E knockout asymmetric dimethylarginine flavin adenine dinucleotide catalases FOXO c-Jun N-terminal kinase HSP DHPR DNTP MT l-NNA FOS small interfering ribonucleic acids MAPK GPx PCD NOX CAT ROS angiotensin SAH y+L AA 6-pyruvoyl tetrahydropterin synthase SAM l-NMMA dihydropteridine reductase NADPH NO ascorbate anion tetrahydrobiopterin estimated glomerular filtration rate LTL thioredoxin glutathione diabetes mellitus tocopherol neuronal tryptophan hydroxylase Finkel–Biskis–Jinkins osteosarcoma siRNAs LDL reactive oxygen species DMA reactive nitrogen species l-arginine GSH antioxidant response element eGFR OS Ref-1 phenylalanine hydroxylase FAD GP guanosine triphosphate S-adenosyl-l-methionine low-density lipoprotein trihydrobiopterin radical 8-Oxoguanine DNA glycosylase tHcy cardiovascular disease free radicals BH 4 |
| Language | English |
| License | CC BY 4.0 2013. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c528t-19091d2b7488410a2afa4dbf868b3affa840d2ccd7fbf7fc5e2a12c97418b0d33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-5176-5121 0000-0002-5763-4579 0000-0001-9973-8803 0000-0003-4009-776X |
| OpenAccessLink | https://ube.hal.science/hal-03434261 |
| PMID | 23859953 |
| PQID | 1443411324 |
| PQPubID | 23479 |
| PageCount | 19 |
| ParticipantIDs | hal_primary_oai_HAL_hal_03434261v1 proquest_miscellaneous_1733527684 proquest_miscellaneous_1443411324 pubmed_primary_23859953 pascalfrancis_primary_27863985 crossref_primary_10_1016_j_pharmthera_2013_07_004 crossref_citationtrail_10_1016_j_pharmthera_2013_07_004 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-12-01 |
| PublicationDateYYYYMMDD | 2013-12-01 |
| PublicationDate_xml | – month: 12 year: 2013 text: 2013-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford |
| PublicationPlace_xml | – name: Oxford – name: England |
| PublicationTitle | Pharmacology & therapeutics (Oxford) |
| PublicationTitleAlternate | Pharmacol Ther |
| PublicationYear | 2013 |
| Publisher | Elsevier |
| Publisher_xml | – name: Elsevier |
| References | Krause (10.1016/j.pharmthera.2013.07.004_bb0395) 2007; 113 Vergely (10.1016/j.pharmthera.2013.07.004_bb0870) 2003; 420 Kielstein (10.1016/j.pharmthera.2013.07.004_bb0360) 2003; 107 Schramm (10.1016/j.pharmthera.2013.07.004_bb0745) 2012; 56 Reaven (10.1016/j.pharmthera.2013.07.004_bb0645) 2003; 88 Gomes (10.1016/j.pharmthera.2013.07.004_bb0245) 2002; 21 Thum (10.1016/j.pharmthera.2013.07.004_bb0820) 2007; 56 Bedford (10.1016/j.pharmthera.2013.07.004_bb0065) 2009; 33 Antoniades (10.1016/j.pharmthera.2013.07.004_bb0040) 2011; 124 Davids (10.1016/j.pharmthera.2013.07.004_bb0175) 2012; 302 Michel (10.1016/j.pharmthera.2013.07.004_bb0525) 2010; 459 Pasini (10.1016/j.pharmthera.2013.07.004_bb0620) 2008; 21 Ushio-Fukai (10.1016/j.pharmthera.2013.07.004_bb0845) 1996; 271 Satoh (10.1016/j.pharmthera.2013.07.004_bb0725) 2005; 288 Vergely (10.1016/j.pharmthera.2013.07.004_bb0865) 1998; 24 Uriu-Adams (10.1016/j.pharmthera.2013.07.004_bb0840) 2005; 26 Pal (10.1016/j.pharmthera.2013.07.004_bb0600) 2007; 26 Turan (10.1016/j.pharmthera.2013.07.004_bb0830) 2012; 44 Virdis (10.1016/j.pharmthera.2013.07.004_bb0885) 2002; 40 Siroen (10.1016/j.pharmthera.2013.07.004_bb0780) 2006; 26 Matter (10.1016/j.pharmthera.2013.07.004_bb0520) 2004; 24 Cha (10.1016/j.pharmthera.2013.07.004_bb0125) 2012; 16 Korandji (10.1016/j.pharmthera.2013.07.004_bb0375) 2011; 214 Antoniades (10.1016/j.pharmthera.2013.07.004_bb0050) 2006; 114 Hamed (10.1016/j.pharmthera.2013.07.004_bb0275) 2011; 91 Svajger (10.1016/j.pharmthera.2013.07.004_bb0795) 2012; 31 Roman (10.1016/j.pharmthera.2013.07.004_bb0685) 2006; 281 Aoki (10.1016/j.pharmthera.2013.07.004_bb0055) 2012; 156 Carlstrom (10.1016/j.pharmthera.2013.07.004_bb0120) 2011; 89 Leiper (10.1016/j.pharmthera.2013.07.004_bb0420) 2011; 10 Andersson (10.1016/j.pharmthera.2013.07.004_bb0030) 1999; 126 Delles (10.1016/j.pharmthera.2013.07.004_bb0180) 2002; 15 Yost (10.1016/j.pharmthera.2013.07.004_bb0970) 2011; 5 Heinke (10.1016/j.pharmthera.2013.07.004_bb0280) 2009; 4 Gruber (10.1016/j.pharmthera.2013.07.004_bb0255) 2008; 13 Cardounel (10.1016/j.pharmthera.2013.07.004_bb0115) 2005; 280 Holden (10.1016/j.pharmthera.2013.07.004_bb0300) 2003; 108 Kuzkaya (10.1016/j.pharmthera.2013.07.004_bb0405) 2003; 278 Fadini (10.1016/j.pharmthera.2013.07.004_bb0195) 2013; 36 Goette (10.1016/j.pharmthera.2013.07.004_bb0240) 2012; 154 Xu (10.1016/j.pharmthera.2013.07.004_bb0945) 2007; 116 Puntarulo (10.1016/j.pharmthera.2013.07.004_bb0640) 2005; 26 Feng (10.1016/j.pharmthera.2013.07.004_bb0200) 2010; 53 Lopez (10.1016/j.pharmthera.2013.07.004_bb0470) 2004; 32 Vallance (10.1016/j.pharmthera.2013.07.004_bb0860) 1992; 339 Boger (10.1016/j.pharmthera.2013.07.004_bb0080) 2009; 60 Montezano (10.1016/j.pharmthera.2013.07.004_bb0550) 2012; 110 Vergely (10.1016/j.pharmthera.2013.07.004_bb0875) 2002; 303 Hong (10.1016/j.pharmthera.2013.07.004_bb0305) 2012; 13 Forstermann (10.1016/j.pharmthera.2013.07.004_bb0210) 2012; 33 Luther (10.1016/j.pharmthera.2013.07.004_bb0485) 2011; 32 Saliques (10.1016/j.pharmthera.2013.07.004_bb0695) 2011; 219 Roe (10.1016/j.pharmthera.2013.07.004_bb0675) 2012; 57 Sartorio (10.1016/j.pharmthera.2013.07.004_bb0710) 2007; 50 Katusic (10.1016/j.pharmthera.2013.07.004_bb0350) 2009; 30 Wang (10.1016/j.pharmthera.2013.07.004_bb0900) 2009; 296 Jacobi (10.1016/j.pharmthera.2013.07.004_bb0325) 2008; 294 Duell (10.1016/j.pharmthera.2013.07.004_bb0185) 1997; 8 Martinez-Gonzalez (10.1016/j.pharmthera.2013.07.004_bb0505) 2001; 21 Toyokuni (10.1016/j.pharmthera.2013.07.004_bb0825) 2008; 60 Garcin (10.1016/j.pharmthera.2013.07.004_bb0230) 2008; 4 Halliwell (10.1016/j.pharmthera.2013.07.004_bb0270) 1995; 18 Miyazaki (10.1016/j.pharmthera.2013.07.004_bb0535) 1999; 99 Williams (10.1016/j.pharmthera.2013.07.004_bb0920) 2012; 2012 Zhang (10.1016/j.pharmthera.2013.07.004_bb0990) 2007; 117 Kawata (10.1016/j.pharmthera.2013.07.004_bb0355) 2009; 132 Wadham (10.1016/j.pharmthera.2013.07.004_bb0895) 2009; 5 Werner (10.1016/j.pharmthera.2013.07.004_bb0910) 2011; 438 Fukuda (10.1016/j.pharmthera.2013.07.004_bb0225) 2002; 87 Zairis (10.1016/j.pharmthera.2013.07.004_bb0980) 2012; 98 Rochette (10.1016/j.pharmthera.2013.07.004_bb0670) 2008; 4 Masuda (10.1016/j.pharmthera.2013.07.004_bb0510) 1999; 126 Clermont (10.1016/j.pharmthera.2013.07.004_bb0150) 2003; 17 Vitecek (10.1016/j.pharmthera.2013.07.004_bb0890) 2012; 2012 Oron-Herman (10.1016/j.pharmthera.2013.07.004_bb0575) 2008; 21 Yang (10.1016/j.pharmthera.2013.07.004_bb0960) 2011; 163 Kotthaus (10.1016/j.pharmthera.2013.07.004_bb0390) 2012; 27 Luo (10.1016/j.pharmthera.2013.07.004_bb0480) 2010; 56 Sarna (10.1016/j.pharmthera.2013.07.004_bb0700) 2010; 88 Xia (10.1016/j.pharmthera.2013.07.004_bb0940) 2010; 335 Candipan (10.1016/j.pharmthera.2013.07.004_bb0100) 1996; 16 Rochette (10.1016/j.pharmthera.2013.07.004_bb0665) 2011; 27 Boger (10.1016/j.pharmthera.2013.07.004_bb0075) 2003; 41 Sun (10.1016/j.pharmthera.2013.07.004_bb0790) 2012; 52 Xue (10.1016/j.pharmthera.2013.07.004_bb0950) 2011; 54 Lecour (10.1016/j.pharmthera.2013.07.004_bb0410) 1999; 33 Ben Baouali (10.1016/j.pharmthera.2013.07.004_bb0070) 1994; 16 Rochette (10.1016/j.pharmthera.2013.07.004_bb0660) 2013; 137 Miura (10.1016/j.pharmthera.2013.07.004_bb0530) 2000; 86 Fraccarollo (10.1016/j.pharmthera.2013.07.004_bb0215) 2008; 118 Rees (10.1016/j.pharmthera.2013.07.004_bb0650) 1990; 101 Zhang (10.1016/j.pharmthera.2013.07.004_bb0995) 2012; 52 Imanishi (10.1016/j.pharmthera.2013.07.004_bb0320) 2008; 52 Goonasekera (10.1016/j.pharmthera.2013.07.004_bb0250) 1997; 15 Ueda (10.1016/j.pharmthera.2013.07.004_bb0835) 2003; 92 Heo (10.1016/j.pharmthera.2013.07.004_bb0290) 2010; 53 Wu (10.1016/j.pharmthera.2013.07.004_bb0930) 1998; 336 Oudot (10.1016/j.pharmthera.2013.07.004_bb0580) 2006; 40 Korandji (10.1016/j.pharmthera.2013.07.004_bb0380) 2007; 40 Li (10.1016/j.pharmthera.2013.07.004_bb0430) 2010; 7 Paterniti (10.1016/j.pharmthera.2013.07.004_bb0625) 2010; 88 Jones (10.1016/j.pharmthera.2013.07.004_bb0335) 2006; 8 Fink (10.1016/j.pharmthera.2013.07.004_bb0205) 2006; 58 Nunes (10.1016/j.pharmthera.2013.07.004_bb0565) 2011; 60 Moens (10.1016/j.pharmthera.2013.07.004_bb0540) 2011; 51 Marcovecchio (10.1016/j.pharmthera.2013.07.004_bb0490) 2008; 115 Yan (10.1016/j.pharmthera.2013.07.004_bb0955) 2012; 18 Sicard (10.1016/j.pharmthera.2013.07.004_bb0775) 2008; 42 Cheng (10.1016/j.pharmthera.2013.07.004_bb0140) 2004; 279 Guzik (10.1016/j.pharmthera.2013.07.004_bb0260) 2006; 11 Teerlink (10.1016/j.pharmthera.2013.07.004_bb0810) 2002; 303 Teerlink (10.1016/j.pharmthera.2013.07.004_bb0805) 2009; 60 Bray (10.1016/j.pharmthera.2013.07.004_bb0090) 2004; 79 Palm (10.1016/j.pharmthera.2013.07.004_bb0605) 2007; 293 Richard (10.1016/j.pharmthera.2013.07.004_bb0655) 2008; 52 Gielis (10.1016/j.pharmthera.2013.07.004_bb0235) 2011; 50 Alderton (10.1016/j.pharmthera.2013.07.004_bb0015) 2001; 357 Schulz (10.1016/j.pharmthera.2013.07.004_bb0755) 2008; 10 Antoniades (10.1016/j.pharmthera.2013.07.004_bb0045) 2009; 30 Naseem (10.1016/j.pharmthera.2013.07.004_bb0560) 2005; 26 Yoshimatsu (10.1016/j.pharmthera.2013.07.004_bb0965) 2011; 128 Li (10.1016/j.pharmthera.2013.07.004_bb0435) 2004; 339 Wunderlich (10.1016/j.pharmthera.2013.07.004_bb0935) 2008; 44 Wilcox (10.1016/j.pharmthera.2013.07.004_bb0915) 2012; 59 Selemidis (10.1016/j.pharmthera.2013.07.004_bb0765) 2008; 120 Hingorani (10.1016/j.pharmthera.2013.07.004_bb0295) 1999; 100 Alp (10.1016/j.pharmthera.2013.07.004_bb0020) 2004; 24 Teerlink (10.1016/j.pharmthera.2013.07.004_bb0800) 2005; 10 Thomas (10.1016/j.pharmthera.2013.07.004_bb0815) 2008; 45 Lorgis (10.1016/j.pharmthera.2013.07.004_bb0475) 2010; 213 Ellger (10.1016/j.pharmthera.2013.07.004_bb0190) 2008; 149 Searles (10.1016/j.pharmthera.2013.07.004_bb0760) 2002; 8 Liu (10.1016/j.pharmthera.2013.07.004_bb0455) 2011; 19 Matetzky (10.1016/j.pharmthera.2013.07.004_bb0515) 2003; 163 Crabtree (10.1016/j.pharmthera.2013.07.004_bb0160) 2011; 25 Roede (10.1016/j.pharmthera.2013.07.004_bb0680) 2012; 810 Rossiter (10.1016/j.pharmthera.2013.07.004_bb0690) 2005; 48 Huang (10.1016/j.pharmthera.2013.07.004_bb0315) 1999; 42 Daff (10.1016/j.pharmthera.2013.07.004_bb0170) 2010; 23 Martell (10.1016/j.pharmthera.2013.07.004_bb0495) 2010; 132 Mori (10.1016/j.pharmthera.2013.07.004_bb0555) 1998; 40 Moens (10.1016/j.pharmthera.2013.07.004_bb0545) 2008; 117 Wohlfart (10.1016/j.pharmthera.2013.07.004_bb0925) 2008; 325 Lin (10.1016/j.pharmthera.2013.07.004_bb0445) 2002; 106 Frantz (10.1016/j.pharmthera.2013.07.004_bb0220) 2009; 104 Shimizu (10.1016/j.pharmthera.2013.07.004_bb0770) 2008; 40 Kotsonis (10.1016/j.pharmthera.2013.07.004_bb0385) 2001; 276 Schnabel (10.1016/j.pharmthera.2013.07.004_bb0740) 2005; 97 Cheang (10.1016/j.pharmthera.2013.07.004_bb0130) 2011; 92 Li (10.1016/j.pharmthera.2013.07.004_bb0425) 2013; 21 Abbasi (10.1016/j.pharmthera.2013.07.004_bb0005) 2001; 88 Parry (10.1016/j.pharmthera.2013.07.004_bb0615) 2010; 31 Hagensen (10.1016/j.pharmthera.2013.07.004_bb0265) 2012; 95 Asagami (10.1016/j.pharmthera.2013.07.004_bb0060) 2002; 51 Pi (10.1016/j.pharmthera.2013.07.004_bb0630) 2008; 28 Paiva (10.1016/j.pharmthera.2013.07.004_bb0595) 2003; 52 Kuliszewski (10.1016/j.pharmthera.2013.07.004_bb0400) 2013; 226 Capettini (10.1016/j.pharmthera.2013.07.004_bb0105) 2011; 164 Schulman (10.1016/j.pharmthera.2013.07.004_bb0750) 2006; 295 Cottin (10.1016/j.pharmthera.2013.07.004_bb0155) 1998; 12 Heitzer (10.1016/j.pharmthera.2013.07.004_bb0285) 2000; 43 Onozato (10.1016/j.pharmthera.2013.07.004_bb0570) 2008; 57 Stuhlinger (10.1016/j.pharmthera.2013.07.004_bb0785) 2001; 104 Lonn (10.1016/j.pharmthera.2013.07.004_bb0465) 2006; 354 Vergely (10.1016/j.pharmthera.2013.07.004_bb0880) 2001; 35 Lee (10.1016/j.pharmthera.2013.07.004_bb0415) 2010; 52 Martin (10.1016/j.pharmthera.2013.07.004_bb0500) 2007; 6 Vallance (10.1016/j.pharmthera.2013.07.004_bb0855) 2004; 24 Altenhofer (10.1016/j.pharmthera.2013.07.004_bb0025) 2012; 69 Boger (10.1016/j.pharmthera.2013.07.004_bb0085) 2009; 119 Kim (10.1016/j.pharmthera.2013.07.004_bb0365) 2010; 43 Brittes (10.1016/j.pharmthera.2013.07.004_bb0095) 2010; 163 Huang (10.1016/j.pharmthera.2013.07.004_bb0310) 2013; 56 Yu (10.1016/j.ph |
| References_xml | – volume: 82 start-page: 420 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0735 article-title: Tetrahydrobiopterin protects soluble guanylate cyclase against oxidative inactivation publication-title: Mol Pharmacol doi: 10.1124/mol.112.079855 – volume: 10 start-page: S73 issue: Suppl. 1 year: 2005 ident: 10.1016/j.pharmthera.2013.07.004_bb0800 article-title: ADMA metabolism and clearance publication-title: Vasc Med doi: 10.1177/1358836X0501000111 – volume: 110 start-page: 87 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0550 article-title: Reactive oxygen species and endothelial function—role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases publication-title: Basic Clin Pharmacol Toxicol doi: 10.1111/j.1742-7843.2011.00785.x – volume: 32 start-page: 21 year: 2004 ident: 10.1016/j.pharmthera.2013.07.004_bb0470 article-title: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock publication-title: Crit Care Med doi: 10.1097/01.CCM.0000105581.01815.C6 – volume: 13 start-page: 6554 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0255 article-title: The mitochondrial free radical theory of ageing—where do we stand? publication-title: Front Biosci doi: 10.2741/3174 – volume: 30 start-page: 1142 year: 2009 ident: 10.1016/j.pharmthera.2013.07.004_bb0045 article-title: Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis publication-title: Eur Heart J doi: 10.1093/eurheartj/ehp061 – volume: 60 start-page: 448 year: 2009 ident: 10.1016/j.pharmthera.2013.07.004_bb0805 article-title: Cellular ADMA: regulation and action publication-title: Pharmacol Res doi: 10.1016/j.phrs.2009.08.002 – volume: 116 start-page: 944 year: 2007 ident: 10.1016/j.pharmthera.2013.07.004_bb0945 article-title: Proteasome-dependent degradation of guanosine 5′-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.106.684795 – volume: 69 start-page: 2327 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0025 article-title: The NOX toolbox: validating the role of NADPH oxidases in physiology and disease publication-title: Cell Mol Life Sci doi: 10.1007/s00018-012-1010-9 – volume: 24 start-page: 224 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0610 article-title: Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome publication-title: Nitric Oxide doi: 10.1016/j.niox.2011.03.002 – volume: 54 start-page: 2039 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0950 article-title: Symmetric double-headed aminopyridines, a novel strategy for potent and membrane-permeable inhibitors of neuronal nitric oxide synthase publication-title: J Med Chem doi: 10.1021/jm101071n – volume: 126 start-page: 279 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0730 article-title: Modulating the NO generating system from a medicinal chemistry perspective: current trends and therapeutic options in cardiovascular disease publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2010.02.005 – volume: 18 start-page: 125 year: 1995 ident: 10.1016/j.pharmthera.2013.07.004_bb0270 article-title: The definition and measurement of antioxidants in biological systems publication-title: Free Radic Biol Med doi: 10.1016/0891-5849(95)91457-3 – volume: 52 start-page: 1897 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0790 article-title: Off-target thiol alkylation by the NADPH oxidase inhibitor 3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo[4,5-d]pyrimidine (VAS2870) publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2012.02.046 – volume: 335 start-page: 149 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0940 article-title: Resveratrol reverses endothelial nitric-oxide synthase uncoupling in apolipoprotein E knockout mice publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.110.168724 – volume: 16 start-page: 651 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0125 article-title: Protein arginine methyltransferases (PRMTs) as therapeutic targets publication-title: Expert Opin Ther Targets doi: 10.1517/14728222.2012.688030 – volume: 24 start-page: 470 year: 1998 ident: 10.1016/j.pharmthera.2013.07.004_bb0865 article-title: Influence of the severity of myocardial ischemia on the intensity of ascorbyl free radical release and on post-ischemic recovery during reperfusion publication-title: Free Radic Biol Med doi: 10.1016/S0891-5849(97)00282-7 – volume: 27 start-page: 24 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0390 article-title: Designing modulators of dimethylarginine dimethylaminohydrolase (DDAH): a focus on selectivity over arginase publication-title: J Enzyme Inhib Med Chem doi: 10.3109/14756366.2011.573480 – volume: 88 start-page: 369 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0700 article-title: Berberine inhibits NADPH oxidase mediated superoxide anion production in macrophages publication-title: Can J Physiol Pharmacol doi: 10.1139/Y09-136 – volume: 132 start-page: 286 year: 2009 ident: 10.1016/j.pharmthera.2013.07.004_bb0355 article-title: Effect of angiotensin-converting enzyme inhibitor on serum asymmetric dimethylarginine and coronary circulation in patients with type 2 diabetes mellitus publication-title: Int J Cardiol doi: 10.1016/j.ijcard.2007.08.066 – volume: 45 start-page: 18 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0815 article-title: The chemical biology of nitric oxide: implications in cellular signaling publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2008.03.020 – volume: 156 start-page: 55 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0055 article-title: Fluvastatin upregulates endothelial nitric oxide synthase activity via enhancement of its phosphorylation and expression and via an increase in tetrahydrobiopterin in vascular endothelial cells publication-title: Int J Cardiol doi: 10.1016/j.ijcard.2010.10.029 – volume: 24 start-page: 413 year: 2004 ident: 10.1016/j.pharmthera.2013.07.004_bb0020 article-title: Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.0000110785.96039.f6 – volume: 213 start-page: 616 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0475 article-title: The free oxygen radicals test (FORT) to assess circulating oxidative stress in patients with acute myocardial infarction publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2010.09.018 – volume: 33 start-page: 829 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0210 article-title: Nitric oxide synthases: regulation and function publication-title: Eur Heart J doi: 10.1093/eurheartj/ehr304 – volume: 33 start-page: 78 year: 1999 ident: 10.1016/j.pharmthera.2013.07.004_bb0410 article-title: Electron spin resonance detection of nitric oxide generation in major organs from LPS-treated rats publication-title: J Cardiovasc Pharmacol doi: 10.1097/00005344-199901000-00012 – volume: 32 start-page: 734 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0485 article-title: The renin–angiotensin–aldosterone system and glucose homeostasis publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2011.07.006 – volume: 17 start-page: 1517 year: 1999 ident: 10.1016/j.pharmthera.2013.07.004_bb0705 article-title: Insulin, nitric oxide and the sympathetic nervous system: at the crossroads of metabolic and cardiovascular regulation publication-title: J Hypertens doi: 10.1097/00004872-199917110-00003 – volume: 110 start-page: 281 year: 1979 ident: 10.1016/j.pharmthera.2013.07.004_bb0345 article-title: An investigation of coronary heart disease in families. The Framingham offspring study publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a112813 – volume: 101 start-page: 746 year: 1990 ident: 10.1016/j.pharmthera.2013.07.004_bb0650 article-title: Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo publication-title: Br J Pharmacol doi: 10.1111/j.1476-5381.1990.tb14151.x – volume: 486 start-page: 132 year: 2009 ident: 10.1016/j.pharmthera.2013.07.004_bb0135 article-title: Two synthetic peptides corresponding to the proximal heme-binding domain and CD1 domain of human endothelial nitric-oxide synthase inhibit the oxygenase activity by interacting with CaM publication-title: Arch Biochem Biophys doi: 10.1016/j.abb.2009.03.015 – volume: 8 start-page: 1865 year: 2006 ident: 10.1016/j.pharmthera.2013.07.004_bb0335 article-title: Redefining oxidative stress publication-title: Antioxid Redox Signal doi: 10.1089/ars.2006.8.1865 – volume: 282 start-page: 879 year: 2007 ident: 10.1016/j.pharmthera.2013.07.004_bb0110 article-title: Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function publication-title: J Biol Chem doi: 10.1074/jbc.M603606200 – volume: 53 start-page: 28 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0290 article-title: Emodin and rhein inhibit LIGHT-induced monocytes migration by blocking of ROS production publication-title: Vascul Pharmacol doi: 10.1016/j.vph.2010.03.002 – volume: 13 start-page: 329 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0305 article-title: Tissue-specific and age-dependent expression of protein arginine methyltransferases (PRMTs) in male rat tissues publication-title: Biogerontology doi: 10.1007/s10522-012-9379-2 – volume: 106 start-page: 987 year: 2002 ident: 10.1016/j.pharmthera.2013.07.004_bb0445 article-title: Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase publication-title: Circulation doi: 10.1161/01.CIR.0000027109.14149.67 – volume: 79 start-page: 537 year: 2004 ident: 10.1016/j.pharmthera.2013.07.004_bb0090 article-title: Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity publication-title: Am J Clin Nutr doi: 10.1093/ajcn/79.4.537 – volume: 281 start-page: 23111 year: 2006 ident: 10.1016/j.pharmthera.2013.07.004_bb0685 article-title: Electron transfer by neuronal nitric-oxide synthase is regulated by concerted interaction of calmodulin and two intrinsic regulatory elements publication-title: J Biol Chem doi: 10.1074/jbc.M603671200 – volume: 303 start-page: 131 year: 2002 ident: 10.1016/j.pharmthera.2013.07.004_bb0810 article-title: Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography publication-title: Anal Biochem doi: 10.1006/abio.2001.5575 – volume: 154 start-page: 141 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0240 article-title: The impact of rapid atrial pacing on ADMA and endothelial NOS publication-title: Int J Cardiol doi: 10.1016/j.ijcard.2010.09.004 – volume: 126 start-page: 211 year: 1999 ident: 10.1016/j.pharmthera.2013.07.004_bb0510 article-title: Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0702298 – volume: 50 start-page: 919 year: 2007 ident: 10.1016/j.pharmthera.2013.07.004_bb0710 article-title: Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.107.093450 – volume: 214 start-page: 310 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0375 article-title: Time course of asymmetric dimethylarginine (ADMA) and oxidative stress in fructose-hypertensive rats: a model related to metabolic syndrome publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2010.11.014 – volume: 8 start-page: 28 year: 1997 ident: 10.1016/j.pharmthera.2013.07.004_bb0185 article-title: Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease publication-title: Curr Opin Lipidol doi: 10.1097/00041433-199702000-00007 – volume: 325 start-page: 370 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0925 article-title: Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.107.128009 – volume: 51 start-page: 843 year: 2002 ident: 10.1016/j.pharmthera.2013.07.004_bb0060 article-title: Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes publication-title: Metabolism doi: 10.1053/meta.2002.33349 – volume: 149 start-page: 3148 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0190 article-title: Glycemic control modulates arginine and asymmetrical-dimethylarginine levels during critical illness by preserving dimethylarginine–dimethylaminohydrolase activity publication-title: Endocrinology doi: 10.1210/en.2007-1558 – volume: 104 start-page: 773 year: 2009 ident: 10.1016/j.pharmthera.2013.07.004_bb0220 article-title: The eNOS enhancer AVE 9488: a novel cardioprotectant against ischemia reperfusion injury publication-title: Basic Res Cardiol doi: 10.1007/s00395-009-0041-3 – volume: 11 start-page: 524 year: 2006 ident: 10.1016/j.pharmthera.2013.07.004_bb0260 article-title: Vascular NADPH oxidases as drug targets for novel antioxidant strategies publication-title: Drug Discov Today doi: 10.1016/j.drudis.2006.04.003 – volume: 115 start-page: 361 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0490 article-title: Effect of acute variations of insulin and glucose on plasma concentrations of asymmetric dimethylarginine in young people with Type 1 diabetes publication-title: Clin Sci (Lond) doi: 10.1042/CS20080079 – volume: 60 start-page: 441 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0825 article-title: Molecular mechanisms of oxidative stress-induced carcinogenesis: from epidemiology to oxygenomics publication-title: IUBMB Life doi: 10.1002/iub.61 – volume: 11 start-page: 2535 year: 2009 ident: 10.1016/j.pharmthera.2013.07.004_bb0330 article-title: Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets publication-title: Antioxid Redox Signal doi: 10.1089/ars.2009.2585 – volume: 86 start-page: 203 year: 2000 ident: 10.1016/j.pharmthera.2013.07.004_bb0530 article-title: Antioxidative and prooxidative action of stilbene derivatives publication-title: Pharmacol Toxicol doi: 10.1034/j.1600-0773.2000.d01-36.x – volume: 339 start-page: 183 year: 2004 ident: 10.1016/j.pharmthera.2013.07.004_bb0435 article-title: Effect of endogenous estrogen on endothelial function in women with coronary heart disease and its mechanism publication-title: Clin Chim Acta doi: 10.1016/j.cccn.2003.10.006 – volume: 58 start-page: 8 year: 2006 ident: 10.1016/j.pharmthera.2013.07.004_bb0205 article-title: ESR techniques for the detection of nitric oxide in vivo as an index of endothelial function publication-title: Pharmacol Rep – volume: 26 start-page: 33 year: 2005 ident: 10.1016/j.pharmthera.2013.07.004_bb0560 article-title: The role of nitric oxide in cardiovascular diseases publication-title: Mol Aspects Med doi: 10.1016/j.mam.2004.09.003 – volume: 810 start-page: 249 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0680 article-title: Redox equivalents and mitochondrial bioenergetics publication-title: Methods Mol Biol doi: 10.1007/978-1-61779-382-0_17 – volume: 163 start-page: 1078 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0960 article-title: AVE3085, an enhancer of endothelial nitric oxide synthase, restores endothelial function and reduces blood pressure in spontaneously hypertensive rats publication-title: Br J Pharmacol doi: 10.1111/j.1476-5381.2011.01308.x – volume: 279 start-page: 23892 year: 2004 ident: 10.1016/j.pharmthera.2013.07.004_bb0140 article-title: Small molecule regulators of protein arginine methyltransferases publication-title: J Biol Chem doi: 10.1074/jbc.M401853200 – volume: 42 start-page: 3147 year: 1999 ident: 10.1016/j.pharmthera.2013.07.004_bb0315 article-title: N(omega)-nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase publication-title: J Med Chem doi: 10.1021/jm990111c – volume: 296 start-page: R195 year: 2009 ident: 10.1016/j.pharmthera.2013.07.004_bb0900 article-title: Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension publication-title: Am J Physiol Regul Integr Comp Physiol doi: 10.1152/ajpregu.90506.2008 – volume: 278 start-page: 22546 year: 2003 ident: 10.1016/j.pharmthera.2013.07.004_bb0405 article-title: Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase publication-title: J Biol Chem doi: 10.1074/jbc.M302227200 – volume: 459 start-page: 807 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0525 article-title: Cellular signaling and NO production publication-title: Pflugers Arch doi: 10.1007/s00424-009-0765-9 – volume: 336 start-page: 1 issue: Pt 1 year: 1998 ident: 10.1016/j.pharmthera.2013.07.004_bb0930 article-title: Arginine metabolism: nitric oxide and beyond publication-title: Biochem J doi: 10.1042/bj3360001 – volume: 21 start-page: 1018 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0575 article-title: Metabolic syndrome: comparison of the two commonly used animal models publication-title: Am J Hypertens doi: 10.1038/ajh.2008.218 – volume: 271 start-page: 23317 year: 1996 ident: 10.1016/j.pharmthera.2013.07.004_bb0845 article-title: p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells publication-title: J Biol Chem doi: 10.1074/jbc.271.38.23317 – volume: 10 start-page: 1115 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0755 article-title: Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension publication-title: Antioxid Redox Signal doi: 10.1089/ars.2007.1989 – volume: 15 start-page: 590 year: 2002 ident: 10.1016/j.pharmthera.2013.07.004_bb0180 article-title: Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension publication-title: Am J Hypertens doi: 10.1016/S0895-7061(02)02278-1 – volume: 4 start-page: 255 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0670 article-title: Forgotten radicals in biology publication-title: Int J Biomed Sci doi: 10.59566/IJBS.2008.4255 – volume: 57 start-page: 168 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0675 article-title: Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases publication-title: Vascul Pharmacol doi: 10.1016/j.vph.2012.02.004 – volume: 4 start-page: 69 year: 2009 ident: 10.1016/j.pharmthera.2013.07.004_bb0280 article-title: Virtual screening and biological characterization of novel histone arginine methyltransferase PRMT1 inhibitors publication-title: ChemMedChem doi: 10.1002/cmdc.200800301 – volume: 377 start-page: 884 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0460 article-title: Variance of DDAH/PRMT/ADMA pathway in atrial fibrillation dogs publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2008.10.080 – volume: 295 start-page: 58 year: 2006 ident: 10.1016/j.pharmthera.2013.07.004_bb0750 article-title: l-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial publication-title: JAMA doi: 10.1001/jama.295.1.58 – volume: 53 start-page: 6028 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0200 article-title: Discovery and mechanistic study of a class of protein arginine methylation inhibitors publication-title: J Med Chem doi: 10.1021/jm100416n – volume: 44 start-page: 938 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0935 article-title: The adverse cardiopulmonary phenotype of caveolin-1 deficient mice is mediated by a dysfunctional endothelium publication-title: J Mol Cell Cardiol doi: 10.1016/j.yjmcc.2008.02.275 – volume: 28 start-page: 6 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0630 article-title: Twin layers of lightning: a new role for the chaperone Hsp90 in angiogenesis publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/ATVBAHA.107.156786 – volume: 2012 start-page: 318087 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0890 article-title: Arginine-based inhibitors of nitric oxide synthase: therapeutic potential and challenges publication-title: Mediators Inflamm doi: 10.1155/2012/318087 – volume: 108 start-page: 1575 year: 2003 ident: 10.1016/j.pharmthera.2013.07.004_bb0300 article-title: Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine publication-title: Circulation doi: 10.1161/01.CIR.0000091083.61609.DF – volume: 43 start-page: 584 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0365 article-title: Maintenance of cellular tetrahydrobiopterin homeostasis publication-title: BMB Rep doi: 10.5483/BMBRep.2010.43.9.584 – volume: 21 start-page: 1251 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0620 article-title: Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients publication-title: Am J Hypertens doi: 10.1038/ajh.2008.260 – volume: 420 start-page: 209 year: 2003 ident: 10.1016/j.pharmthera.2013.07.004_bb0870 article-title: Identification and quantification of free radicals during myocardial ischemia and reperfusion using electron paramagnetic resonance spectroscopy publication-title: Arch Biochem Biophys doi: 10.1016/j.abb.2003.07.007 – volume: 52 start-page: 278 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0655 article-title: Effects of angiotensin-1 converting enzyme inhibition on oxidative stress and bradykinin receptor expression during doxorubicin-induced cardiomyopathy in rats publication-title: J Cardiovasc Pharmacol doi: 10.1097/FJC.0b013e3181865f28 – volume: 52 start-page: 563 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0320 article-title: Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.108.111120 – volume: 117 start-page: 2626 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0545 article-title: Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.107.737031 – volume: 60 start-page: 309 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0565 article-title: Monoamine oxidase and semicarbazide-sensitive amine oxidase kinetic analysis in mesenteric arteries of patients with type 2 diabetes publication-title: Physiol Res doi: 10.33549/physiolres.931982 – volume: 48 start-page: 4670 year: 2005 ident: 10.1016/j.pharmthera.2013.07.004_bb0690 article-title: Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase publication-title: J Med Chem doi: 10.1021/jm050187a – volume: 104 start-page: 2569 year: 2001 ident: 10.1016/j.pharmthera.2013.07.004_bb0785 article-title: Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine publication-title: Circulation doi: 10.1161/hc4601.098514 – volume: 56 start-page: 666 year: 2007 ident: 10.1016/j.pharmthera.2013.07.004_bb0820 article-title: Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes publication-title: Diabetes doi: 10.2337/db06-0699 – volume: 303 start-page: 149 year: 2002 ident: 10.1016/j.pharmthera.2013.07.004_bb0875 article-title: Postischemic recovery and oxidative stress are independent of nitric-oxide synthases modulation in isolated rat heart publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.102.036871 – volume: 18 start-page: 676 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0955 article-title: Tetrahydrobiopterin, l-arginine and vitamin C actsynergistically to decrease oxidative stress, increase nitricoxide and improve blood flow after induction of hindlimb ischemia in the rat publication-title: Mol Med doi: 10.2119/molmed.2011.00103 – volume: 51 start-page: 564 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0540 article-title: Bi-modal dose-dependent cardiac response to tetrahydrobiopterin in pressure-overload induced hypertrophy and heart failure publication-title: J Mol Cell Cardiol doi: 10.1016/j.yjmcc.2011.05.017 – volume: 118 start-page: 818 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0215 article-title: Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.107.717702 – volume: 354 start-page: 1567 year: 2006 ident: 10.1016/j.pharmthera.2013.07.004_bb0465 article-title: Homocysteine lowering with folic acid and B vitamins in vascular disease publication-title: N Engl J Med doi: 10.1056/NEJMoa060900 – volume: 113 start-page: 50 year: 2007 ident: 10.1016/j.pharmthera.2013.07.004_bb0395 article-title: Protein arginine methyltransferases: evolution and assessment of their pharmacological and therapeutic potential publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2006.06.007 – volume: 89 start-page: 574 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0120 article-title: Dietary nitrate attenuates oxidative stress, prevents cardiac and renal injuries, and reduces blood pressure in salt-induced hypertension publication-title: Cardiovasc Res doi: 10.1093/cvr/cvq366 – volume: 28 start-page: 637 year: 1996 ident: 10.1016/j.pharmthera.2013.07.004_bb0715 article-title: Immunohistochemical localization of facilitated-diffusion glucose transporters in rat pancreatic islets publication-title: Tissue Cell doi: 10.1016/S0040-8166(96)80067-X – volume: 24 start-page: 662 year: 2004 ident: 10.1016/j.pharmthera.2013.07.004_bb0520 article-title: Biology and chemistry of the inhibition of nitric oxide synthases by pteridine-derivatives as therapeutic agents publication-title: Med Res Rev doi: 10.1002/med.20005 – volume: 7 start-page: 438 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0430 article-title: Role of inflammation and oxidative stress in atrial fibrillation publication-title: Heart Rhythm doi: 10.1016/j.hrthm.2009.12.009 – volume: 36 start-page: 943 issue: 4 year: 2013 ident: 10.1016/j.pharmthera.2013.07.004_bb0195 article-title: Diabetes impairs stem cell and proangiogenic cell mobilization in humans publication-title: Diabetes Care doi: 10.2337/dc12-1084 – volume: 91 start-page: 9 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0275 article-title: Nitric oxide: a key factor behind the dysfunctionality of endothelial progenitor cells in diabetes mellitus type-2 publication-title: Cardiovasc Res doi: 10.1093/cvr/cvq412 – volume: 99 start-page: 1141 year: 1999 ident: 10.1016/j.pharmthera.2013.07.004_bb0535 article-title: Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis publication-title: Circulation doi: 10.1161/01.CIR.99.9.1141 – volume: 5 start-page: 72 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0970 article-title: Targets in epigenetics: inhibiting the methyl writers of the histone code publication-title: Curr Chem Genomics doi: 10.2174/1875397301005010072 – volume: 107 start-page: 1891 year: 2003 ident: 10.1016/j.pharmthera.2013.07.004_bb0360 article-title: Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects publication-title: Circulation doi: 10.1161/01.CIR.0000060496.23144.A7 – volume: 293 start-page: H3227 year: 2007 ident: 10.1016/j.pharmthera.2013.07.004_bb0605 article-title: Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems publication-title: Am J Physiol Heart Circ Physiol doi: 10.1152/ajpheart.00998.2007 – volume: 30 start-page: 48 year: 2009 ident: 10.1016/j.pharmthera.2013.07.004_bb0350 article-title: Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2008.10.003 – volume: 30 start-page: 935 year: 2009 ident: 10.1016/j.pharmthera.2013.07.004_bb0450 article-title: The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats publication-title: Acta Pharmacol Sin doi: 10.1038/aps.2009.58 – volume: 19 start-page: 283 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0455 article-title: JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.12.020 – volume: 44 start-page: 281 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0830 article-title: Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies publication-title: J Bioenerg Biomembr doi: 10.1007/s10863-012-9429-0 – volume: 124 start-page: 335 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0040 article-title: Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.110.985150 – volume: 21 start-page: 1147 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0370 article-title: NADPH oxidase inhibitors: a patent review publication-title: Expert Opin Ther Pat doi: 10.1517/13543776.2011.584870 – volume: 16 start-page: 223 year: 1994 ident: 10.1016/j.pharmthera.2013.07.004_bb0070 article-title: Plasma lipid peroxidation in critically ill patients: importance of mechanical ventilation publication-title: Free Radic Biol Med doi: 10.1016/0891-5849(94)90147-3 – volume: 21 start-page: 575 year: 2002 ident: 10.1016/j.pharmthera.2013.07.004_bb0245 article-title: Homocysteine increase after acute myocardial infarction—can it explain the differences between case-control and cohort studies? publication-title: Rev Port Cardiol – volume: 12 start-page: 116 issue: Suppl. 2 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0340 article-title: Redox compartmentalization and cellular stress publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2010.01266.x – volume: 8 start-page: 155 issue: 142–147 year: 2002 ident: 10.1016/j.pharmthera.2013.07.004_bb0760 article-title: The nitric oxide pathway and oxidative stress in heart failure publication-title: Congest Heart Fail – volume: 10 start-page: 277 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0420 article-title: The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis publication-title: Nat Rev Drug Discov doi: 10.1038/nrd3358 – volume: 52 start-page: 303 year: 2003 ident: 10.1016/j.pharmthera.2013.07.004_bb0595 article-title: Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy publication-title: Metabolism doi: 10.1053/meta.2003.50048 – volume: 41 start-page: 1467 year: 2003 ident: 10.1016/j.pharmthera.2013.07.004_bb0075 article-title: Association of asymmetric dimethylarginine and endothelial dysfunction publication-title: Clin Chem Lab Med doi: 10.1515/CCLM.2003.225 – volume: 26 start-page: 299 year: 2005 ident: 10.1016/j.pharmthera.2013.07.004_bb0640 article-title: Iron, oxidative stress and human health publication-title: Mol Aspects Med doi: 10.1016/j.mam.2005.07.001 – volume: 5 start-page: 303 year: 2009 ident: 10.1016/j.pharmthera.2013.07.004_bb0895 article-title: Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease publication-title: Expert Opin Drug Metab Toxicol doi: 10.1517/17425250902785172 – volume: 28 start-page: 954 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0985 article-title: Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/ATVBAHA.108.162768 – volume: 88 start-page: 2399 year: 2003 ident: 10.1016/j.pharmthera.2013.07.004_bb0645 article-title: Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2003-030087 – volume: 6 start-page: 165 year: 2007 ident: 10.1016/j.pharmthera.2013.07.004_bb0500 article-title: Abnormalities of mitochondrial functioning can partly explain the metabolic disorders encountered in sarcopenic gastrocnemius publication-title: Aging Cell doi: 10.1111/j.1474-9726.2007.00271.x – volume: 98 start-page: 860 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0980 article-title: Plasma asymmetric dimethylarginine and mortality in patients with acute decompensation of chronic heart failure publication-title: Heart doi: 10.1136/heartjnl-2011-301372 – volume: 59 start-page: 375 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0915 article-title: Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.111.187310 – volume: 25 start-page: 81 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0160 article-title: Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease publication-title: Nitric Oxide doi: 10.1016/j.niox.2011.04.004 – volume: 97 start-page: e53 year: 2005 ident: 10.1016/j.pharmthera.2013.07.004_bb0740 article-title: Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study publication-title: Circ Res doi: 10.1161/01.RES.0000181286.44222.61 – volume: 137 start-page: 133 year: 2013 ident: 10.1016/j.pharmthera.2013.07.004_bb0660 article-title: Carbon monoxide: mechanisms of action and potential clinical implications publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2012.09.007 – volume: 92 start-page: 267 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0130 article-title: Endothelial nitric oxide synthase enhancer reduces oxidative stress and restores endothelial function in db/db mice publication-title: Cardiovasc Res doi: 10.1093/cvr/cvr233 – volume: 276 start-page: 49133 year: 2001 ident: 10.1016/j.pharmthera.2013.07.004_bb0385 article-title: Structural basis for pterin antagonism in nitric-oxide synthase. Development of novel 4-oxo-pteridine antagonists of (6R)-5,6,7,8-tetrahydrobiopterin publication-title: J Biol Chem doi: 10.1074/jbc.M011469200 – volume: 33 start-page: 1 year: 2009 ident: 10.1016/j.pharmthera.2013.07.004_bb0065 article-title: Protein arginine methylation in mammals: who, what, and why publication-title: Mol Cell doi: 10.1016/j.molcel.2008.12.013 – volume: 163 start-page: 1933 year: 2003 ident: 10.1016/j.pharmthera.2013.07.004_bb0515 article-title: Association of elevated homocysteine levels with a higher risk of recurrent coronary events and mortality in patients with acute myocardial infarction publication-title: Arch Intern Med doi: 10.1001/archinte.163.16.1933 – volume: 294 start-page: H1058 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0325 article-title: Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice publication-title: Am J Physiol Heart Circ Physiol doi: 10.1152/ajpheart.01103.2007 – volume: 163 start-page: 747 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0095 article-title: Effects of resveratrol on membrane biophysical properties: relevance for its pharmacological effects publication-title: Chem Phys Lipids doi: 10.1016/j.chemphyslip.2010.07.004 – volume: 31 start-page: 164 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0615 article-title: Protein arginine methylation: a new handle on T lymphocytes? publication-title: Trends Immunol doi: 10.1016/j.it.2010.01.006 – volume: 358 start-page: 2127 year: 2001 ident: 10.1016/j.pharmthera.2013.07.004_bb0850 article-title: Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine publication-title: Lancet doi: 10.1016/S0140-6736(01)07184-7 – volume: 55 start-page: 7978 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0905 article-title: Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation publication-title: J Med Chem doi: 10.1021/jm300521m – volume: 40 start-page: 2214 year: 2006 ident: 10.1016/j.pharmthera.2013.07.004_bb0580 article-title: NADPH oxidases are in part responsible for increased cardiovascular superoxide production during aging publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2006.02.020 – volume: 52 start-page: 341 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0995 article-title: Sub-cellular targeting of constitutive NOS in health and disease publication-title: J Mol Cell Cardiol doi: 10.1016/j.yjmcc.2011.09.006 – volume: 43 start-page: 1435 year: 2000 ident: 10.1016/j.pharmthera.2013.07.004_bb0285 article-title: Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus publication-title: Diabetologia doi: 10.1007/s001250051551 – volume: 120 start-page: 254 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0765 article-title: NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2008.08.005 – volume: 42 start-page: 226 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0775 article-title: Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats publication-title: Free Radic Res doi: 10.1080/10715760701885380 – volume: 280 start-page: 7540 year: 2005 ident: 10.1016/j.pharmthera.2013.07.004_bb0115 article-title: Endogenous methylarginines modulate superoxide as well as nitric oxide generation from neuronal nitric-oxide synthase: differences in the effects of monomethyl- and dimethylarginines in the presence and absence of tetrahydrobiopterin publication-title: J Biol Chem doi: 10.1074/jbc.M410241200 – volume: 26 start-page: 3558 year: 2007 ident: 10.1016/j.pharmthera.2013.07.004_bb0600 article-title: Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma publication-title: EMBO J doi: 10.1038/sj.emboj.7601794 – volume: 219 start-page: 753 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0695 article-title: Circulating leukocyte telomere length and oxidative stress: a new target for statin therapy publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2011.09.011 – volume: 60 start-page: 481 year: 2009 ident: 10.1016/j.pharmthera.2013.07.004_bb0080 article-title: Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality—an update on patient populations with a wide range of cardiovascular risk publication-title: Pharmacol Res doi: 10.1016/j.phrs.2009.07.001 – volume: 117 start-page: 2658 year: 2007 ident: 10.1016/j.pharmthera.2013.07.004_bb0990 article-title: Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk publication-title: J Clin Invest doi: 10.1172/JCI31093 – volume: 12 start-page: 236 year: 1998 ident: 10.1016/j.pharmthera.2013.07.004_bb0155 article-title: Plasma iron status and lipid peroxidation following thrombolytic therapy for acute myocardial infarction publication-title: Fundam Clin Pharmacol doi: 10.1111/j.1472-8206.1998.tb00947.x – volume: 302 start-page: H1762 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0175 article-title: Role of the human erythrocyte in generation and storage of asymmetric dimethylarginine publication-title: Am J Physiol Heart Circ Physiol doi: 10.1152/ajpheart.01205.2011 – volume: 294 start-page: H1530 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0165 article-title: Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS publication-title: Am J Physiol Heart Circ Physiol doi: 10.1152/ajpheart.00823.2007 – volume: 92 start-page: 226 year: 2003 ident: 10.1016/j.pharmthera.2013.07.004_bb0835 article-title: Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase publication-title: Circ Res doi: 10.1161/01.RES.0000052990.68216.EF – volume: 119 start-page: 1592 year: 2009 ident: 10.1016/j.pharmthera.2013.07.004_bb0085 article-title: Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.108.838268 – volume: 438 start-page: 397 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0910 article-title: Tetrahydrobiopterin: biochemistry and pathophysiology publication-title: Biochem J doi: 10.1042/BJ20110293 – volume: 31 start-page: 202 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0795 article-title: Anti-inflammatory effects of resveratrol and its potential use in therapy of immune-mediated diseases publication-title: Int Rev Immunol doi: 10.3109/08830185.2012.665108 – volume: 56 start-page: 216 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0745 article-title: Targeting NADPH oxidases in vascular pharmacology publication-title: Vascul Pharmacol doi: 10.1016/j.vph.2012.02.012 – volume: 5 start-page: e9462 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0010 article-title: Sequence variation in DDAH1 and DDAH2 genes is strongly and additively associated with serum ADMA concentrations in individuals with type 2 diabetes publication-title: PLoS One doi: 10.1371/journal.pone.0009462 – volume: 23 start-page: 1 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0170 article-title: NO synthase: structures and mechanisms publication-title: Nitric Oxide doi: 10.1016/j.niox.2010.03.001 – volume: 35 start-page: 475 year: 2001 ident: 10.1016/j.pharmthera.2013.07.004_bb0880 article-title: Isolated perfused rat hearts release secondary free radicals during ischemia reperfusion injury. Cardiovascular effect of the spin trap alpha-phenyl N-tert-butylnitrone publication-title: Free Radic Res doi: 10.1080/10715760100301491 – volume: 40 start-page: 113 year: 1998 ident: 10.1016/j.pharmthera.2013.07.004_bb0555 article-title: Intra-coronary administration of l-arginine aggravates myocardial stunning through production of peroxynitrite in dogs publication-title: Cardiovasc Res doi: 10.1016/S0008-6363(98)00146-1 – volume: 40 start-page: 504 year: 2002 ident: 10.1016/j.pharmthera.2013.07.004_bb0885 article-title: Spironolactone improves angiotensin-induced vascular changes and oxidative stress publication-title: Hypertension doi: 10.1161/01.HYP.0000034738.79310.06 – volume: 56 start-page: 3024 issue: 7 year: 2013 ident: 10.1016/j.pharmthera.2013.07.004_bb0310 article-title: Structure-guided design of selective inhibitors of neuronal nitric oxide synthase publication-title: J Med Chem doi: 10.1021/jm4000984 – volume: 46 start-page: 412 year: 2000 ident: 10.1016/j.pharmthera.2013.07.004_bb0590 article-title: l-arginine administration prevents reperfusion-induced cardiomyocyte hypercontracture and reduces infarct size in the pig publication-title: Cardiovasc Res doi: 10.1016/S0008-6363(00)00048-1 – volume: 88 start-page: 1201 year: 2001 ident: 10.1016/j.pharmthera.2013.07.004_bb0005 article-title: Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus publication-title: Am J Cardiol doi: 10.1016/S0002-9149(01)02063-X – volume: 16 start-page: 44 year: 1996 ident: 10.1016/j.pharmthera.2013.07.004_bb0100 article-title: Regression or progression. Dependency on vascular nitric oxide publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.16.1.44 – volume: 87 start-page: 264 year: 2002 ident: 10.1016/j.pharmthera.2013.07.004_bb0225 article-title: Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia publication-title: Heart doi: 10.1136/heart.87.3.264 – volume: 100 start-page: 1515 year: 1999 ident: 10.1016/j.pharmthera.2013.07.004_bb0295 article-title: A common variant of the endothelial nitric oxide synthase (Glu298→Asp) is a major risk factor for coronary artery disease in the UK publication-title: Circulation doi: 10.1161/01.CIR.100.14.1515 – volume: 17 start-page: 709 year: 2003 ident: 10.1016/j.pharmthera.2013.07.004_bb0150 article-title: Direct demonstration of nitric oxide formation in organs of rabbits treated by transdermal glyceryl trinitrate using an in vivo spin trapping technique publication-title: Fundam Clin Pharmacol doi: 10.1046/j.1472-8206.2003.00199.x – volume: 2012 start-page: 656247 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0920 article-title: Nitric oxide manipulation: a therapeutic target for peripheral arterial disease? publication-title: Cardiol Res Pract doi: 10.1155/2012/656247 – volume: 50 start-page: 765 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0235 article-title: Pathogenetic role of eNOS uncoupling in cardiopulmonary disorders publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2010.12.018 – volume: 26 start-page: 203 year: 2006 ident: 10.1016/j.pharmthera.2013.07.004_bb0780 article-title: The clinical significance of asymmetric dimethylarginine publication-title: Annu Rev Nutr doi: 10.1146/annurev.nutr.26.061505.111320 – volume: 21 start-page: 804 year: 2001 ident: 10.1016/j.pharmthera.2013.07.004_bb0505 article-title: 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.21.5.804 – volume: 150 start-page: 893 year: 2007 ident: 10.1016/j.pharmthera.2013.07.004_bb0585 article-title: Nitric oxide fails to confer endogenous antiarrhythmic cardioprotection in the primate heart in vitro publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0707143 – volume: 128 start-page: 562 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0965 article-title: Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers publication-title: Int J Cancer doi: 10.1002/ijc.25366 – volume: 132 start-page: 798 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0495 article-title: Heme-coordinating inhibitors of neuronal nitric oxide synthase. Iron-thioether coordination is stabilized by hydrophobic contacts without increased inhibitor potency publication-title: J Am Chem Soc doi: 10.1021/ja908544f – volume: 27 start-page: 497 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0665 article-title: Atrial and vascular oxidative stress in patients with heart failure publication-title: Cell Physiol Biochem doi: 10.1159/000329951 – volume: 6 start-page: 204 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0975 article-title: The role of the methoxyphenol apocynin, a vascular NADPH oxidase inhibitor, as a chemopreventative agent in the potential treatment of cardiovascular diseases publication-title: Curr Vasc Pharmacol doi: 10.2174/157016108784911984 – volume: 357 start-page: 593 year: 2001 ident: 10.1016/j.pharmthera.2013.07.004_bb0015 article-title: Nitric oxide synthases: structure, function and inhibition publication-title: Biochem J doi: 10.1042/0264-6021:3570593 – volume: 164 start-page: 1738 year: 2011 ident: 10.1016/j.pharmthera.2013.07.004_bb0105 article-title: Decreased production of neuronal NOS-derived hydrogen peroxide contributes to endothelial dysfunction in atherosclerosis publication-title: Br J Pharmacol doi: 10.1111/j.1476-5381.2011.01500.x – volume: 126 start-page: 1639 year: 1999 ident: 10.1016/j.pharmthera.2013.07.004_bb0030 article-title: A nitric oxide-mediated mechanism regulates lipolysis in human adipose tissue in vivo publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0702430 – volume: 24 start-page: 1023 year: 2004 ident: 10.1016/j.pharmthera.2013.07.004_bb0855 article-title: Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.0000128897.54893.26 – volume: 7 start-page: e36224 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0035 article-title: A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with insulin sensitivity publication-title: PLoS One doi: 10.1371/journal.pone.0036224 – volume: 21 start-page: 1333 year: 2013 ident: 10.1016/j.pharmthera.2013.07.004_bb0425 article-title: Cyclopropyl- and methyl-containing inhibitors of neuronal nitric oxide synthase publication-title: Bioorg Med Chem doi: 10.1016/j.bmc.2012.12.019 – volume: 56 start-page: 498 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0480 article-title: Angiotensin II and NADPH oxidase increase ADMA in vascular smooth muscle cells publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.110.152959 – volume: 26 start-page: 268 year: 2005 ident: 10.1016/j.pharmthera.2013.07.004_bb0840 article-title: Copper, oxidative stress, and human health publication-title: Mol Aspects Med doi: 10.1016/j.mam.2005.07.015 – volume: 4 start-page: 700 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0230 article-title: Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase publication-title: Nat Chem Biol doi: 10.1038/nchembio.115 – volume: 40 start-page: 66 year: 2007 ident: 10.1016/j.pharmthera.2013.07.004_bb0380 article-title: Asymmetric dimethylarginine (ADMA) and hyperhomocysteinemia in patients with acute myocardial infarction publication-title: Clin Biochem doi: 10.1016/j.clinbiochem.2006.08.004 – volume: 88 start-page: 993 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0625 article-title: Protective effects of apocynin, an inhibitor of NADPH oxidase activity, in splanchnic artery occlusion and reperfusion publication-title: J Leukoc Biol doi: 10.1189/jlb.0610322 – volume: 95 start-page: 281 year: 2012 ident: 10.1016/j.pharmthera.2013.07.004_bb0265 article-title: Arterial endothelial cells: still the craftsmen of regenerated endothelium publication-title: Cardiovasc Res doi: 10.1093/cvr/cvs182 – volume: 60 start-page: 461 year: 2009 ident: 10.1016/j.pharmthera.2013.07.004_bb0635 article-title: Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production publication-title: Pharmacol Res doi: 10.1016/j.phrs.2009.07.016 – volume: 114 start-page: 1193 year: 2006 ident: 10.1016/j.pharmthera.2013.07.004_bb0050 article-title: 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.106.612325 – volume: 263 start-page: 517 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0440 article-title: The molecular mechanisms of the thrombotic complications of atherosclerosis publication-title: J Intern Med doi: 10.1111/j.1365-2796.2008.01965.x – volume: 339 start-page: 572 year: 1992 ident: 10.1016/j.pharmthera.2013.07.004_bb0860 article-title: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure publication-title: Lancet doi: 10.1016/0140-6736(92)90865-Z – volume: 23 start-page: 3806 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0720 article-title: Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfn357 – volume: 57 start-page: 172 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0570 article-title: Expression of NG, NG-dimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers publication-title: Diabetes doi: 10.2337/db06-1772 – volume: 15 start-page: 901 year: 1997 ident: 10.1016/j.pharmthera.2013.07.004_bb0250 article-title: Nitric oxide synthase inhibitors and hypertension in children and adolescents publication-title: J Hypertens doi: 10.1097/00004872-199715080-00015 – volume: 52 start-page: 1290 year: 2010 ident: 10.1016/j.pharmthera.2013.07.004_bb0415 article-title: Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells publication-title: J Vasc Surg doi: 10.1016/j.jvs.2010.04.085 – volume: 226 start-page: 58 issue: 1 year: 2013 ident: 10.1016/j.pharmthera.2013.07.004_bb0400 article-title: A direct comparison of endothelial progenitor cell dysfunction in rat metabolic syndrome and diabetes publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2012.09.029 – volume: 40 start-page: 755 year: 2008 ident: 10.1016/j.pharmthera.2013.07.004_bb0770 article-title: Hydrogen peroxide stimulates tetrahydrobiopterin synthesis through activation of the Jak2 tyrosine kinase pathway in vascular endothelial cells publication-title: Int J Biochem Cell Biol doi: 10.1016/j.biocel.2007.10.011 – volume: 288 start-page: F1144 year: 2005 ident: 10.1016/j.pharmthera.2013.07.004_bb0725 article-title: NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy publication-title: Am J Physiol Renal Physiol doi: 10.1152/ajprenal.00221.2004 – volume: 116 start-page: 428 year: 2007 ident: 10.1016/j.pharmthera.2013.07.004_bb0145 article-title: l-arginine transporters in cardiovascular disease: a novel therapeutic target publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2007.08.001 |
| SSID | ssj0004402 |
| Score | 2.5907645 |
| SecondaryResourceType | review_article |
| Snippet | Nitric oxide (NO) is synthetized enzymatically from l-arginine (l-Arg) by three NO synthase isoforms, iNOS, eNOS and nNOS. The synthesis of NO is selectively... Nitric oxide (• NO) is synthetized enzymatically from L-arginine (L-Arg) by three NO synthase isoforms, iNOS, eNOS and nNOS. The synthesis of NO is selectively... |
| SourceID | hal proquest pubmed pascalfrancis crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 239 |
| SubjectTerms | active sites Animals Biological and medical sciences calmodulin Cardiology and cardiovascular system Cardiovascular Diseases - drug therapy Cardiovascular Diseases - enzymology Cardiovascular Diseases - metabolism Cardiovascular system diabetes endothelial nitric oxide synthase enzyme activity enzyme inhibition Enzyme Inhibitors - pharmacology Enzyme Inhibitors - therapeutic use free radicals heme Human health and pathology Humans hypertension inducible nitric oxide synthase ischemia Life Sciences Medical sciences Miscellaneous neuronal nitric oxide synthase nitric oxide Nitric Oxide - metabolism Nitric Oxide Synthase - antagonists & inhibitors Nitric Oxide Synthase - metabolism oxidation oxidative stress Oxidative Stress - drug effects Pharmacology. Drug treatments protein degradation regulatory proteins therapeutics |
| Title | Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: Possible therapeutic targets? |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/23859953 https://www.proquest.com/docview/1443411324 https://www.proquest.com/docview/1733527684 https://ube.hal.science/hal-03434261 |
| Volume | 140 |
| WOSCitedRecordID | wos000326422200003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1879-016X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004402 issn: 0163-7258 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6jgckhLhTLpVBaC9dpiR2YocXVI2NbpSqgiFVe4mcxFE7RWm1XlT-Nz-A4zjXMVB54CWqnDhJcz775Djf-Q5C7xwpLXBLzDBJaBtUUmp4geMZ4Aw5pZHHRJhJ5g_ZaMQnE2_cav0scmE2CUtTvt16i_9qamgDY6vU2X8wd3lSaIDfYHTYgtlhu5PhRzMlut-bb2eRVIIEqyk4qt4snc6C2aogH6u9WvI7TxZRdPQmNTX_dJNR5sZzNXQS2aula_U0iXx5gxo4rrSwNRmn1iVb4dUpirUViK-qaNdKl-kbrsOSIqSogUUKdwm_S1nkLn6BKF-kFSvg01oVUNLr5OdSpMZxItaRrC9rWOQGRaTIt6kvfbrEYLYWej-St7QV87nWf8qBS-qzs9ZNyh29rZWxf_Mhejnj6mihnlf2jBQDkGQar7pUclO2e9D_5o8_nvrDs9Hn5t4a13HQH8J2KhIYFJSouHUDMfu-zRyPt9F-_-xkcl7l89KMK1v-u5yBpnmJt99W47Vqb6pIvfcWABiRxLpAy58jqOxN6uIBup-HQLivofsQtWT6CB3kuPlxiC9qgDnEB7iOqMdorvGNM3zjAt-4wjcGDOAS31jjG_bjJr5xge_3uEA3rkEV5-j-8AR9Pz25OB4YedUQI3RsvjLgDdezIjtg4JqoZQpbxIJGQcxdHhARx4JTM7LDMGJxELM4dKQtLDv0lIxTYEaEPEXtdJ7K5wjDdGUFbswgJifUIS6n0MllsReZruCu6CBWPHQ_zCX1VWWXxC-4k1d-ZS5fmcs3Fd-DdpBV9lxoWZkd-rwFu5aHK114QJWv2ipMdVC3YfbycJtxNf86HfSmwIEPnkR9HhSpnK-XvkXhJJYFEdZfjmEqR1N9vO-gZxpE1RUIV-qF5MUu9_kS3a1G_SvUXl2v5Wt0J9ysZsvrLtpjE97Nh8UvFikEDw |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nitric+oxide+synthase+inhibition+and+oxidative+stress+in+cardiovascular+diseases%3A+Possible+therapeutic+targets%3F&rft.jtitle=Pharmacology+%26+therapeutics+%28Oxford%29&rft.au=Rochette%2C+Luc&rft.au=Lorin%2C+Julie&rft.au=Zeller%2C+Marianne&rft.au=Guilland%2C+Jean-Claude&rft.date=2013-12-01&rft.pub=Elsevier&rft.issn=0163-7258&rft.eissn=0163-7258&rft.volume=140&rft.issue=3&rft.spage=239&rft.epage=257&rft_id=info:doi/10.1016%2Fj.pharmthera.2013.07.004&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=oai%3AHAL%3Ahal-03434261v1 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0163-7258&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0163-7258&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0163-7258&client=summon |